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 ABSTRACT 
Lysosomal aspartylglucosaminidase (AGA) participates in glycoprotein breakdown by 
catalyzing cleavage of the N-glycosidic bond between asparagine and N-
acetylglucosamine. Mutations in the AGA gene lead to a lysosomal storage disease, 
aspartylglucosaminuria (AGU), which is characterized by progressive mental retardation of 
patients. The recessively inherited disease is enriched in the Finnish population.  
 
Prior to this study, the three-dimensional crystal structure and the catalytic mechanism of 
human AGA had been determined (Oinonen et al. 1995, Tikkanen et al. 1996a). For the 
activation of AGA, dimerization of AGA precursor polypeptides had been proposed to be 
required (Riikonen et al. 1996). However, detailed knowledge of the initial steps of the 
maturation of AGA was however lacking. This study was carried out to characterize the 
dimerization process and the autocatalytic activation mechanism of AGA in detail.  
 
The native AGA molecule consists of two αβ-dimers in close contact. The dimer interface 
is rather flat and the dimers are linked by non-covalent interactions. On the dimer interface, 
three regions of amino acids were found to provide an abundance of contacts between the 
dimers. Mutagenesis of these regions prevented dimerization and activation of precursor 
molecules.  
 
Site-directed mutagenesis at the activation site revealed that the side chain hydroxyl group 
of T206 is required for activation of the AGA precursor polypeptides. In addition, correct 
conformation of the polypeptide backbone between the scissile D205-T206 peptide bond is 
crucial for triggering the activation, using the energy contained in a high-energy strained 
peptide bond. Other active site amino acids also contribute to the activation by forming a 
structural scaffold which stabilizes the residues directly involved in autocatalysis. On the 
basis of these studies, a reaction mechanism for the activation of AGA was proposed. 
 
Seven novel AGU mutations were found, including mutations in three Finnish and four non-
Finnish patients. These and the majority of the previously found AGU mutations were 
expressed in vitro and their consequences at the polypeptide structural level were 
characterized in detail. These data will help in dissecting the molecular pathogenesis of the 
AGU disease. 
 
Finally, the expression and purification of the recombinant human AGA precursor has 
provided material for crystallization experiments, which hopefully will lead to determination 
of the structure of the human AGA precursor molecule. 
 REVIEW OF THE LITERATURE 
1. Lysosomes 
Lysosomes, discovered in 1955, are the terminal degradative compartment of the 
endocytic pathway and are also involved in phagocytosis and autophagy (de Duve et al. 
1955, de Duve 1983, Kornfeld and Mellman 1989). These cytoplasmic acidic vesicles 
surrounded by a single membrane are rich in hydrolytic enzymes, which are used for the 
controlled intracellular digestion of macromolecules (Novikoff 1963). Acidic environment of 
pH 4.6-5.0 is maintained by H+ ATPase at the lysosomal membrane, and membrane 
potential is dissipated by influx of Cl- and efflux of K+ and Na+, providing an optimal 
environment for at least 50 types of acid hydrolases in the lysosomal lumen (Bainton 1981, 
Mellman et al. 1986, Stevens and Forgac 1997). Lysosomes are very diverse in size and 
shape and their identification can be performed by histochemical visualization of acid 
phosphatase (de Duve 1963). The diversity reflects the wide variety of digestive functions 
mediated by acid hydrolases  the breakdown of intracellular and endocytosed debris, the 
destruction of phagocytosed microorganisms, and the production of nutrients for the cell. 
The resulting free amino acids, lipids, and oligosaccharides can be used as substrates for 
synthesis of new macromolecules or for degradation as sources of energy. The action of 
lysosomal hydrolases finally results in complete degradation of macromolecules into 
monomeric residues. Specific transporters in the lysosomal membrane move them out of 
the lysosomes to be metabolically reused (Saier 1999). Recently, a better understanding of 
the endocytic pathway has challenged the function of lysosomes. The current hypothesis 
indicates that lysosomes, defined by the absence of mannose 6-phosphate receptors, are 
actually storage granules for acid hydrolases. The digestion of endocytosed 
macromolecules is proposed to occur in hybrid vesicles that are formed by fusion of 
lysosomes and late endosomes (Luzio et al. 2000). Additionally, in many cell types 
lysosomes are capable of fusion with the plasma membrane to secrete their contents 
(Stinchcombe and Griffiths 1999). 
 
2. Protein folding, modification, and degradation 
Proteins entering the secretory pathway  including proteins of the endoplasmic reticulum, 
Golgi, endosomes/lysosomes, nuclear and plasma membranes, and extracellular space - 
are synthesized on the cytoplasmic side of the endoplasmic reticulum (ER) membrane in 
ribosomes. Recognized by their signal sequence, these newly synthesized proteins are 
translocated into the lumen of the ER through the translocon complex, a proteinaceous 
channel through which the emerging chain enters the ER lumen or integrates with the ER 
membrane. The lumen of the ER contains molecular chaperones and folding factors that 
 assist protein folding in all stages. In the ER, several co-translational and post-translational 
modifications take place, which are important for correct protein folding and transport.  
 
2.1. Protein folding 
Protein folding starts co-translationally as the nascent proteins are being synthesized at 
the ribosomes. Folding typically occurs in three stages. First, co-translational and co-
translocational protein folding occurs in the translocon complex, a membrane protein 
complex utilized to insert the nascent polypeptide chain into the membrane and transfer 
soluble polypeptides across the lipid bilayer. Early stages of protein folding proceed 
quickly, for secondary structure formation and compaction of the structure require much 
less than one second (Roder and Colon 1997). Post-translational folding takes place after 
the completed chain has been released from the ribosome and the translocon complex. 
The resulting molten globules are more open and less ordered than the final folded form of 
the protein (Feng et al. 1994). Finally, when the subunits have reached a conformation that 
is close to the final folded state, oligomeric assembly takes place.  
 
Instead of beginning from a random coil or extended state, folding is kick started by 
native-like topology and intermolecular interactions (Dobson 1992, Blanco et al. 1998, 
Baldwin 2002). For most proteins, polypeptide synthesis requires between 20 seconds and 
several minutes (Fedorov and Baldwin 1998). As a consequence, compact intermediates 
are formed in the process of synthesis. Binding of cofactors and ligands, for example 
oligosaccharides, often stabilizes protein structure and can affect the folding pathways 
(Kim et al. 1991, Chen et al. 1995). In the later stages of polypeptide folding, disulfide 
bonds are formed.  
 
The hydrophobic core of the protein molecule is tightly packed in solution and amino acid 
changes caused by mutations must be compensated by surrounding neighbors (Chothia 
1975). The last stage of protein folding involves the ordering of amino acid side chains into 
a well-defined and closely packed configuration to maximize noncovalent interactions 
(Richards 1974). At this point the overall fold has already been determined, dictated largely 
by hydrophobic interactions in the early stages of folding, and the side chains are close to 
their final positions (Kuwajima 1996). Overall, protein folding is still not well understood, 
although some basic principles have been described (Daggett and Fersht 2003). 
 
2.11. Chaperones 
Molecular chaperones are ubiquitous components of cells that assist the folding of many 
proteins. Chaperones decrease protein aggregation by binding aggregation-prone 
intermediates, unfolding nonproductive folding intermediates, and assisting the polypeptide 
 in overcoming energy barriers in the folding reaction (Buchner 1996, Fedorov and Baldwin 
1997). The majority of the currently known chaperones belong to three highly conserved 
heat-shock protein families (hsp70, hsp90, and hsp60), whose members are widely 
distributed from prokaryotes to plants and mammals (Gething and Sambrook 1992). 
Chaperones are found in the cytosol, ER, mitochondria, and nucleus of eukaryotic cells. 
These proteins are present in great abundance under normal growth conditions, but can be 
further induced by heat shock or other forms of stress. Members of the hsp70 family are 
associated with the nascent polypeptides, recognizing abnormally exposed patches of 
hydrophobic amino acids on the surface of target proteins (Beckmann et al. 1990). BiP, a 
special hsp70 protein, helps to fold proteins in the ER by stabilizing prefolded structures 
and aiding in completion of translocation (Vogel et al. 1990, Blount and Merlie 1991). BiP 
associates transiently with nascent wild-type (WT) proteins and more permanently with 
misfolded or unassembled proteins (Hurtley et al. 1989). The bacterial GroEL/GroES 
system is a well-characterized example of hsp60-aided protein folding (Grallert and 
Buchner 2001). 
 
Some other chaperones have been implicated in binding nascent chains of particular 
groups of proteins. Calnexin, a chaperone in the ER membrane, binds transiently to some 
glycoproteins and is required for their correct folding and assembly (Chen et al. 1995). 
Calreticulin, a soluble protein of the ER lumen, and calnexin bind to sugar moieties on 
nascent glycoproteins through their globular lectin domain (Hammond and Helenius 1995). 
Monoglycosylated forms of target proteins bind to calnexin and/or calreticulin, until 
released in deglycosylated form by glucosidase II, that acts specifically on folded 
glycoproteins (Hebert et al. 1995, Ellgaard and Helenius 2003). UDP-glucose:glycoprotein 
glycosyltransferase reglycosylates unfolded proteins so that they can reassociate with 
calnexin/calreticulin. A simple model suggests that proteins bound to chaperones are safe 
from proteolysis and that the rounds of binding and release from chaperones assist protein 
maturation (Farr et al. 1997). Folded proteins in the ER are released to traverse the 
secretory pathway, but retained unfolded proteins are captured by the degradative 
machinery. In the disposal pathway, mannosidase I slowly acts on misfolded proteins and 
directs them for degradation (Jakob et al. 1998, Liu et al. 1999). Subsequent interaction 
with ER-degradation-enhancing 1,2-mannosidase-like protein probably diverts the 
glycoprotein from the calnexin/calreticulin cycle and promotes its degradation (Hosokawa 
et al. 2001). The ER quality control system is important for the fidelity of cellular functions, 
as quite a large fraction of the ER-synthesized proteins fail to fold and mature properly. 
Additionally, an incomplete quality control system underlies several genetic disorders, 
since proteins with amino acid substitutions often fail to fold correctly, leading to ER 
retention and degradation of misfolded proteins (Aridor and Hannan 2000, 2002). 
 
 Protein disulfide isomerase (PDI), a folding catalyst, facilitates formation of the correct set 
of disulfide bonds by promoting rapid reshuffling of incorrect disulfide pairings. PDI can 
catalyze thiol/disulfide interchange reactions and promotes protein disulfide formation, 
isomerization, or reduction of nascent polypeptides in vivo (Roth and Pierce 1987). 
Peptidyl-prolyl isomerases (PPIases), residing in the cytosol and ER of eukaryotes, form 
transient complexes with nascent polypeptides and accelerate the folding of proline-
containing polypeptides (Klappa et al. 1995).  
 
2.2. Protein modification 
Common post-translational modifications include proteolytic cleavage, glycosylation, 
acylation and fatty acid modification, phosphorylation, methylation, sulfation, disulfide bond 
formation, deamidation, ubiquitination, and acetylation (Mann and Jensen 2003). 
Glycosylation is an important and very common post-translational modification in 
eukaryotic proteins. It plays a key role for many proteins during folding and stabilizes 
proteins (Kaushal et al. 1994, Busca et al. 1995). In addition, glycosylation has a role in 
protein targeting, cell-cell recognition and signaling, and it serves other regulatory 
functions. The glycosyl transferase pathway in the Golgi synthesizes oligosaccharides O-
linked to serine, threonine, or hydroxylysine. The predominant type of glycosylation in 
mammals is N-linked glycosylation, where specific asparagine residues of the polypeptide 
within the consensus sequence, Asn-X-Ser/Thr (in which X can be any residue except 
proline), are attached to an oligosaccharide moiety (Marshall 1974). N-linked 
oligosaccharides are attached to the amide group of asparagine residues in the lumen of 
the ER by a dolichol-linked pathway. The oligosaccharide moiety is then trimmed in the ER 
and further modifications and additions occur in the Golgi, depending on the protein 
(Kornfeld and Kornfeld 1985, Aronson and Kuranda 1989). The N-linked oligosaccharide 
core consists of two N-acetylglucosamine (GlcNAc) and three mannose residues, shown in 
Figure 1. In the high mannose type of glycoconjugates the terminal region of the 
oligosaccharide chain initially consists of six additional mannose residues, while in the 
complex type oligosaccharides the terminal regions contain GlcNac, galactose, sialic acid, 
and in some cases fucose residues (Kornfeld and Kornfeld 1976). Hybrid type 
oligosaccharides are a mixture of these types. Defects of glycosylation may result in 
disease. Examples include a lethal form of Marfan syndrome resulting from a point 
mutation which creates an extra consensus sequence for N-glycosylation that appears to 
be utilized in the patients cells (Lönnqvist et al. 1996). Congenital disorders of 
glycosylation lead to the development of severe multi-system disorders. Congenital 
disorders of N-glycosylation are divided into two types: Type 1, where the deficiencies are 
in the assembly of the core oligosaccharide, and type 2, where the defects are in the 
modification of the core oligosaccharide (Aridor and Hannan 2002). Defects in O-
glycosylation cause, for example, the Ehlers-Danlos syndrome (Quentin et al. 1990). 
  
 
 
Figure 1. The structure of complex, hybrid type, and high mannose oligosaccharide 
chains. The lysosomal hydrolytic glycosidases involved in their degradation are: A) 
aspartylglucosaminidase, B) α-fucosidase, C) endo-β-N-acetyl-glucosaminidase or β-
hexosaminidase A or B, D) β-mannosidase, E) β-hexosaminidase A or B, F) α-
mannosidase, G) β-hexosaminidase A or B, H) β-galactosidase, and I) α-neuraminidase. 
The common pentasaccharide core is indicated within a box. Modified with permission 
from Scriver, C.R, Beaudet, A.L., Sly, W.S., and Valle, D. (Eds.) (2001) The metabolic and 
molecular basis of inherited disease, pp. 3510, and King, M.W. 2003 (WWW-Page, 
modified 12.2.2003) The Medical Biochemistry Page, 
http://www.indstate.edu/thcme/mwking/protein-modifications.html. 
 
2.3. Degradation of misfolded proteins 
The cellular folding machinery competes with a different system that transfers proteins 
containing exposed patches of hydrophobic amino acids to proteasomes for complete 
destruction. Protein degradation represents the last chance for a cell to suppress the 
potentially toxic effects of aberrant proteins. It has been suggested that cells stressed by 
heat shock might die not because of the loss of protein activity due to their denaturation, 
but because of the toxicity of the denatured proteins (Friant et al. 2003). For example, it is 
essential that non-functional or partially functional ion channels and receptors do not reach 
the plasma membrane, where their presence could be toxic (Zerangue et al. 1999). The 
cytosolic ubiquitin/proteasome pathway helps clear misfolded proteins (Finley and Chau 
1991). Ubiquitin, a small protein, is covalently conjugated onto a lysine residue of a target 
protein by ubiquitin-conjugating enzyme. Subsequently, more ubiquitin is added to form a 
polyubiquitin chain. Polyubiquitinated proteins are recognized and rapidly degraded by the 
 proteasomes (Hiller et al. 1996), which are located in the cytosol and the nucleus. 
Monoubiquitylation seems to function as a reversible non-proteolytic modification that 
controls protein function in endocytic trafficking (Hicke 2001). Persistently misfolded 
glycoproteins of the ER lumen undergo ER-associated degradation, where misfolded 
proteins are retro-translocated to the cytosol and degraded by the proteasomes 
(McCracken and Brodsky 1996, Kopito 1997). Mutant presenilin-1 protein is known to 
cause familial Alzheimers disease. It downregulates the signalling pathway, the unfolded-
protein response, that adjusts levels of molecular chaperones in response to stress 
(Katayama et al. 1999). The ER quality control system seems unable to deal with heavily 
aggregated proteins (Braakman et al. 1992, Rivera et al. 2000). Aggregates in the ER may 
compromise cell function, but in many cases may not cause immediate cell death - so they 
may be similar to inclusion bodies in the cytosol, which are also relatively benign.  
 
3. Intracellular transport of soluble lysosomal proteins 
Once secretory proteins are correctly folded, they enter the ER exit sites and are packaged 
into coatomer protein (COP)-II coated vesicles (Barlowe 2002). Transport from the ER to 
the cis-face of the Golgi occurs in COP-II vesicles via the ER-Golgi intermediate 
compartment (Saraste and Kuismanen 1984) while transport in the opposite direction 
(retrograde) occurs in COP-I-coated vesicles (Semenza et al. 1990). The ER-to-Golgi 
movement of transport vesicles, when visualized by live-cell microscopy, occurs along 
microtubules using the dynein/dynactin motor complex (Presley et al. 1997). In the trans-
Golgi network (TGN), lysosomal enzymes are separated from secretory proteins and 
transported to the endosomes and then to the lysosomes. Clathrin-coated vesicles mediate 
traffic between the cell surface, TGN, and the endosomes. Clathrin forms the outer surface 
of these coats, while adaptor protein (AP) complexes bind clathrin, the coat accessory 
factors and the cytosolic tails of the transmembrane proteins. The clathrin coat is shed 
rapidly after vesicle formation. The lysosomal proteins are phosphorylated in the cis-Golgi 
by UDP-N-acetylglucosamine-lysosomal enzyme-N-acetylglucosamine-
phosphotransferase, which attaches an N-acetylglucosamine-phosphate group to 
mannose residues (Hasilik et al. 1981, Reitman and Kornfeld 1981, Bao et al. 1996a, Bao 
et al. 1996b). Mucolipidosis IIIC has been reported to be caused by mutations in the 
phosphotransferase γ-subunit gene (Raas-Rothschild et al. 2000). The oligosaccharides 
are further modified in the Golgi, where N-acetylglucosamine-1-phosphodiester-α-N-
acetylglucosaminidase removes the GlcNAc group and the lysosomal targeting signal, 
mannose 6-phosphate, is exposed (Waheed et al. 1981). Soluble lysosomal enzymes are 
sorted into lysosomes by mannose 6-phosphate receptors (MPR) in the trans-Golgi (Figure 
2).  
 
 The transmembrane receptors are themselves directed through intracellular transport 
pathways by sorting determinants in their cytoplasmic domains. The AP-1 complex 
mediates MPR sorting at TGN, while AP-3 acts in MPR retrieval from endosomes (Pearse 
and Robinson 1990, Dell'Angelica et al. 1998). AP-1 may also function in retrieval from 
endosomes. The AP-2 complex functions in endocytic clathrin coated vesicle formation 
(Robinson 1994, Le Borgne and Hoflack 1998). Two distinct but related MPRs with 
complementary functions have been described: 300 kDa cation-independent MPR (CI-
MPR) (Sahagian et al. 1981) and 46 kDa cation-dependent MPR (CD-MPR) (Hoflack and 
Kornfeld 1985). Both receptors are required for efficient intracellular targeting of lysosomal 
enzymes and the receptors may interact in vivo with distinct but overlapping subsets of 
phosphorylated ligands (Ludwig et al. 1994). MPRs are type-1 integral membrane 
glycoproteins with mannose 6-phosphate binding sites in the extracytoplasmic region 
(Dahms and Hancock 2002, Hancock et al. 2002). The cytoplasmic tails of both receptors 
contain numerous sorting signals, some of which are modified by phosphorylation 
(Rosorius et al. 1993) or palmitoylation (Schweizer et al. 1996). The CD-MPR undergoes 
significant structural changes upon ligand binding (Olson et al. 2002). The two receptors 
use a similar carbohydrate-recognition mechanism (Roberts et al. 1998, Hancock et al. 
2002). MPRs loaded with ligands are sorted from the secretory pathway by selective 
incorporation into tubulo-vesicular structures that emerge from the TGN and ferry cargo to 
endosomes.  
 
Between early and late endosomes, ligands dissociate from MPRs and are delivered to 
even more acidic lysosomes, while MPRs are retrieved to the TGN to pick up more cargo 
(Mellman et al. 1986). Extracellular, missorted mannose 6-phosphate-tagged enzymes are 
recruited by CI-MPR and directed to the endocytic pathway (Helenius et al. 1983). CI-MPR 
also binds and internalizes IGF-II growth factor at the cell surface, thus regulating cell 
growth (Kiess et al. 1988, Wang et al. 1994). In the endocytic pathway, incoming material 
encounters progressively decreasing pH as it moves through the prelysosomal 
compartments towards the lysosomes. The acidic pH of the lysosomes helps to denature 
the proteins destined to be degraded. Proteins sequestered within the lysosomes turn over 
with an apparent half-life of about eight minutes (Mortimore et al. 1988). However, 
lysosomal enzymes have a relatively long half-life in spite of their harsh surroundings. 
Defects in generation of the lysosomal sorting signal cause diseases. For example, cells 
affected with the I-cell disease are deficient in GlcNAc-phosphotransferase activity, which 
results in secretion of soluble lysosomal enzymes from the cells into the extracellular milieu 
(Reitman et al. 1981, Mueller et al. 1983). 
 
  
 
Figure 2. Transport of newly synthesized proteins along the mannose 6-phosphate 
receptor pathway. Newly synthesized lysosomal enzymes are translocated into the lumen 
of the ER. The enzymes are transported through the ER-Golgi intermediate compartment 
to the cis-face of the Golgi complex. In the Golgi, N-linked oligosaccharides of soluble 
lysosomal proteins are labelled with mannose 6-phosphate and the exposed mannose 6-
phosphate marker is recognized and bound by the mannose 6-phosphate receptors. The 
trans-Golgi network is the sorting station of the secretory pathway and lysosomal enzymes 
are delivered to the endosomes. Extracellular lysosomal enzymes are bound to the 
receptor on the cell surface and endocytosed. In the endosomes, the receptor-ligand 
complex is broken and the receptors are retrieved and recycled back to the Golgi. 
Extracellular lysosomal enzymes can be endocytosed from the plasma membrane by 
mannose 6-phosphate receptors and transported to the lysosomes via endosomes. 
 
 4. Aspartylglucosaminidase (AGA) 
4.1. Properties and purification of AGA 
Aspartylglucosaminidase (AGA, glycosylasparaginase, N4-(β-N-Acetylglucosaminyl)-L-
Asparaginase, EC 3.5.1.26) is a lysosomal hydrolase that participates in the breakdown of 
glycoproteins. Sequential digestion of both the polypeptide backbone and the asparagine-
linked oligosaccharide moieties by lysosomal hydrolases results in free amino acid 
residues and glycosylated asparagines, the latter being substrates of AGA. Specifically, 
AGA cleaves the amido bond between the N-linked oligosaccharide and the asparagine 
residue (Makino et al. 1966, Tikkanen et al. 1996a). AGA only hydrolyses substrates with 
free α-carboxyl and α-amino groups on L-asparagine but the asparagine-linked 
carbohydrate chain can be of high mannose, hybrid, or complex type (Makino et al. 1968, 
Tarentino et al. 1975, Kaartinen et al. 1992). However, fucosylated complex-type N-
glycans are not hydrolyzed by AGA (Tarentino et al. 1975, Yamashita et al. 1979, 
Noronkoski and Mononen 1997). The hydrolysis reaction of the natural substrate, 2-
acetamido-1-β-(L-aspartamido)-1,2-dideoxy-D-glucose (AADG), catalyzed by AGA 
produces aspartic acid and aminoglycan and subsequently the aminoglycan part of the 
substrate hydrolyzes nonenzymatically to release oligosaccharide and ammonia (Makino 
et al. 1968). The released oligosaccharides are degraded by lysosomal exoglycosidases, 
which remove sugars from the nonreducing ends of oligosaccharides (Aronson and 
Kuranda 1989) as illustrated in Figure 1. Specific deficiencies of these enzymes result in 
glycoprotein or oligosaccharide storage diseases (Cantz and Ulrich-Bott 1990). AGA has 
other catalytic functions as well. AGA catalyzes the synthesis and degradation of β-
aspartyl peptides (Noronkoski et al. 1998). In addition, it catalyzes the hydrolysis of L-
asparagine, which competitively inhibits the hydrolysis of glycosylated asparagines 
(Noronkoski et al. 1997). Other inhibitors of AGA include L-aspartate and its analogues, 
transition state mimics, AADG analogues (Risley et al. 2001a), and 5-diazo-4-oxo-L-
norvaline (Tarentino and Maley 1969, Tarentino et al. 1975, Tollersrud et al. 1988, 
Kaartinen et al. 1991). 
 
AGA has been partially purified and characterized from the guinea pig serum (Makino et al. 
1966), the rat liver (Mahadevan and Tappel 1967), the pig serum (Makino et al. 1968), the 
chicken oviduct (Tarentino and Maley 1969), and the pig kidney (Kohno and Yamashina 
1972). AGA was purified to homogeneity for the first time in 1989 from human (Baumann 
et al. 1989) and rat (Tollersrud and Aronson 1989) liver. The human AGA enzyme has 
been purified to homogeneity from the liver (Baumann et al. 1989, Rip et al. 1992), urine 
(Kaartinen 1991), and leukocytes (Halila et al. 1991, Kaartinen et al. 1991, Heiskanen et al. 
1994, Tollersrud et al. 1994a, Tikkanen et al. 1996b). The kinetic parameters (Kaartinen et 
al. 1991, Tikkanen et al. 1996a, Risley et al. 2001b) and specific activity of human AGA 
 have also been reported (Kaartinen et al. 1991). The activity assay for AGA is based on 
colorimetric measurement of the N-acetylglucosamine liberated from the substrate, AADG 
(Reissig et al. 1955). A sensitive fluorometric assay has also been developed (Mononen et 
al. 1993). The pH optimum of human AGA is between 5.5 and 6 (Baumann et al. 1989, 
Tollersrud and Aronson 1992), while for rat and mouse AGA the optimum is between 7 and 
9 (Kaartinen et al. 1991, Tollersrud and Aronson 1992). The human enzyme also has high 
activity between pH values 7 and 9 (Tikkanen et al. 1996a). However, at the lysosomal pH, 
generally below 5, considerable AGA activity also exists (Oinonen et al. 1995). The 
reaction mechanism for AGA-catalyzed amidohydrolysis of glycosylated asparagines is 
known (Tikkanen et al. 1996a) and is well supported by the pH optimum. This has raised 
suspicions that AGA might have functions outside of lysosomes. For example, involvement 
in the myelination of the brain neurons has been suggested (Uusitalo et al. 1999). The 
AGA enzyme is stable in the cells, since the half-life of the rat liver AGA is two days 
(Tollersrud et al. 1988). WT AGA is very heat-stable and resistant to denaturation by SDS 
(Tollersrud and Aronson 1989, Enomaa et al. 1992), features utilized in the purification of 
the active enzyme (Heiskanen et al. 1994, Tollersrud et al. 1994b, Tikkanen et al. 1996b). 
 
4.2. The AGA gene 
The human AGA gene was physically mapped to the region 4q21-qter of chromosome 4 in 
1984 (Aula et al. 1984). Later, the gene was linked to a marker at 4q28-31 (Grön et al. 
1990) and the location was defined by in-situ hybridization methods to 4q32-33 (Morris et 
al. 1992). The 2.1 kb cDNA was cloned and characterized in the early 1990s by two groups 
(Fisher et al. 1990, Ikonen et al. 1991b). The first mutation resulting in human 
aspartylglucosaminuria disease was also identified (Ikonen et al. 1991b). Both subunits of 
the 346 amino acid polypeptide were found to be coded by the single gene of 1041 bp. The 
AGA cDNA contains a 949 bp 3 untranslated region (UTR) (Ikonen et al. 1991b) and 
human and mouse AGA contain approximately 900 bp of a homologous region upstream 
of the ATG translation initiation codon (Uusitalo et al. 1997). The transcription starts 298 
upstream of the ATG codon. Two mRNA species (2.1 kb and 1.4 kb) have been identified 
in human tissues, which could be explained by the use of alternative polyadenylation sites 
of the 3 UTR (Ikonen et al. 1991b). The human AGA enzyme is present in very small 
quantities in all tissues, as it is encoded by a housekeeping gene (Enomaa et al. 1992, 
Uusitalo et al. 1997).  
 
The genomic structure of the 13 kb AGA gene was solved in 1991 (Park et al. 1991). The 
gene contains nine exons, several transcriptional elements, and an inhibitory region in the 
5 UTR (Uusitalo et al. 1997). The AGA gene has been found in various organisms from 
bacteria to mammals: the bacterium Flavobacterium meningosepticum (Tarentino and 
Plummer 1993), the butterfly Spodoptera frugiperda (Liu et al. 1996), and the mouse 
 (Tenhunen et al. 1995). An evolutionary relationship also exists with a plant asparaginase 
from the plant Lupinus arboreus (Lough et al. 1992). In addition, homologs of the human 
AGA gene have been detected in rat (Conchie and Strachan 1969, Tollersrud and Aronson 
1989, Liu et al. 1996), pig, cow, and chicken (Tollersrud and Aronson 1992, Liu et al. 
1996). The human genome project (special issues Science 15 February 2001, Nature 16 
February 2001, Science 11 April 2003, and Nature 24 April 2003) has provided a sequence 
of the human genome with 99.9% of the genome covered. In the database, the human 
AGA gene is found in 4q32-33 and the gene spans 10668 bp plus 5 and 3 UTR regions 
(http://www.ncbi.nlm.nih.gov/, NT 022792). The AGA genomic sequence provided by the 
international consortium contains a few errors; for example, in exon 4 S159 is changed to 
threonine in the genomic sequence.  
 
4.3. Dimerization and autoproteolysis of AGA precursors 
AGA is synthesized as an inactive precursor molecule, which is rapidly cleaved into α- and 
β- subunits (Ikonen et al. 1993). The molecule is simultaneously activated as the critical α-
amino group of T206 is exposed. Dimerization of two inactive precursor molecules is 
suggested to be the event triggering autoproteolytic activation (Riikonen et al. 1996). 
Dimerization takes place either when the polypeptides have reached a conformation that is 
close to the final folded state or during the early stages of folding. Certain mutations of the 
AGA polypeptide result in lack of dimerization and subsequent activation (Riikonen et al. 
1996). The analyzed AGA polypeptides with mutations of the active site are not drastically 
misfolded as they are transported to the lysosomes (see 4.4) (Peltola et al. 1996, Tikkanen 
et al. 1996a). The activation of AGA has been implicated to occur autocatalytically 
(Oinonen et al. 1995, Peltola et al. 1996, Tikkanen et al. 1996a). Since the activation site of 
AGA is located at the bottom of the active site funnel, it is unlikely that an external protease 
could reach the scissile peptide bond (Tikkanen et al. 1996a).  
 
4.4. Intracellular processing and transport of AGA 
The AGA gene encodes an inactive 346-amino-acid precursor polypeptide from which a 
23-amino-acid signal sequence is cleaved co-translationally (Figure 3). Two precursor 
molecules dimerize and the precursor molecules are normally cleaved into the N-terminal 
α- (27 kDa) and C-terminal β- (17 kDa) subunits (Ikonen et al. 1993, Riikonen et al. 1995). 
The molecule also obtains its full enzymatic activity. The AGA polypeptides migrate 
abnormally on SDS-PAGE due to lack of sufficient binding to SDS (Tollersrud and Aronson 
1989, Tollersrud et al. 1994a), which has historically created problems regarding the 
determination of the precise molecular mass. A high-mannose type of oligosaccharide 
chain is Nlinked to each AGA subunit at residues N38 and N308 (Tollersrud and Aronson 
1989, Tikkanen et al. 1995). The active tetrameric molecule is transported to the 
 lysosomes, using the mannose 6-phosphate pathway (Tikkanen et al. 1995, Park et al. 
1996b, Tikkanen et al. 1997). The same pathway is also utilized by neuronal cells (Kyttälä 
et al. 1998). The C-terminal parts of the human α- and β-subunits are trimmed in the 
lysosomes by lysosomal proteases (Peltola et al. 1996). This processing pattern of AGA 
can be easily used to monitor the intracellular transport of AGA polypeptides. Some 
disease-causing mutations of AGA cause abnormal processing of the precursor, where 
activation does not occur but the molecule is transported to the lysosomes and cleaved 
(Peltola et al. 1996, Tikkanen et al. 1996a). Even in these mutations, the AGA molecule is 
folded sufficiently correctly to be transported to the lysosomes, since the three-dimensional 
structure determines whether the phosphorylation of AGA oligosaccharides occurs 
(Tikkanen et al. 1997). UDP-N-acetylglucosamine phosphotransferase recognizes 
lysosomal proteins on the basis of a surface structural determinant. On the surface of the 
human AGA molecule, the determinant is formed by three co-operating and separate areas 
containing lysine residues and oligosaccharide chains (Tikkanen et al. 1997). The 
interaction with phosphotransferase is co-operative and all recognition sites have to be in 
correct spatial position; thus, only correctly folded AGA molecules are phosphorylated and 
transported to the lysosomes. AGA, like other lysosomal enzymes, is also secreted and 
subsequently endocytosed by adjacent cells (Enomaa et al. 1995). AGA molecules without 
oligosaccharides are active but are secreted (Tikkanen et al. 1995).  
  
 
 
Figure 3. The processing of human AGA. The signal peptide is cleaved co-translationally 
in the ER from the AGA preproprotein, resulting in a monomeric precursor polypeptide 
(proprotein). The normal autocatalytic processing pathway is represented on the left, and 
the abnormal nonactivating pathway caused by processing failure on the right. The 
apparent molecular weight determined from SDS-PAGE is shown in parentheses. Two 
precursor molecules dimerize in the ER prior to the activation cleavage, which produces 
the two αβ-dimers of mature AGA. Copyright (1998) American Society for Biochemistry 
and Molecular Biology, USA. 
 
4.5. Structure and reaction mechanism of human AGA 
The three-dimensional crystal structure of native human AGA was determined at 2.0 Å 
resolution by Oinonen et al. (1995). The active AGA molecule is an (αβ)2 tetramer with 
50*50*70 Å dimensions (1apy, Protein Data Bank, http://www.rcsb.org/pdb/). The molecule 
is comprised of two almost identical heterodimeric αβ- domains packed together (Figure 4). 
The core structure of the domains contains an αββα-sandwich, where antiparallel β-
strands are packed between α-helical layers. The domains contain four intramolecular 
disulfide bridges (C64-C69; C163-C179; C286-C306; C317-C345) and are noncovalently 
bound to each other. The interface between the domains is relatively flat and contains over 
200 unique contacts. The upper part of the AGA structure forms a plateau which consists 
of the C-terminal loops of both α-subunits, the AGUFin-loops. This loop contains two α-
 helices and a disulfide bridge in addition to irregularly folded structures. The 
heterotetrameric molecule of AGA contains two active sites, one in each domain. The 
refined crystal structure of AGA in a complex with the reaction product, aspartate, was 
solved at 2.3 Å resolution (Oinonen et al. 1995). The active site is funnel-shaped; the 
asparagine part of the substrate is bound at the bottom and the oligosaccharide part is 
bound in the upper and wider part of the funnel, which explains the structural requirements 
of the substrate. The active site of AGA contains residues from both subunits and the 
residues are located in loops connecting the different α- and β-layers. T206 functions as 
the catalytic nucleophile in the substrate hydrolysis reaction and its properties are 
influenced by hydrogen bonds from S72 and T224. T257 and G258 stabilize the negatively 
charged reaction intermediate with hydrogen bonds (the oxyanion hole), while the 
substrate asparagine is bound by hydrogen bonds from T206, R234, D237, T257, and 
G258 (Oinonen et al. 1995). The catalytic site of AGA has no typical serine protease-like 
catalytic triad (Tikkanen et al. 1996a). In the serine proteases, the catalytic triad is formed 
by Ser (reacting nucleophile)  His (base)  Asp (oxyanion hole: charge relay and 
stabilization) (Matthews et al. 1967, Warshel et al. 1989). The key catalytic residue of AGA, 
T206, is located at the N-terminus of the β-subunit and has a dual function. The 
prerequisite for the reaction is the uncharged NH2 state of the α-amino group of T206, 
which is consistent with the measured pH optimum of AGA (pH 7-9). The reaction is shown 
in Figure 5. The reaction mechanisms of serine proteases and of AGA have similar 
features and both serine proteases and AGA use specific and non-specific substrate 
binding. In addition, the acylation step of the reaction has been proposed to be rate-limiting 
in AGA catalyzed substrate hydrolysis as well as in serine proteases (Du and Risley 2003). 
 
  
 
Figure 4. Overall quaternary structure of WT human AGA. One αβ-heterodimer is red (α-
subunit) and green (β-subunit), while the other dimer is blue. The disulfide bridges are 
shown in yellow. The reaction product, aspartate, is shown in one active site. The 
glycosylation sites, one in each subunit, are shown with one GlcNAc residue. Modified 
from Oinonen et al. 1995. 
 
  
 
Figure 5. The catalytic reaction mechanism of human AGA. The α-amino group of T206 
acts as the base and increases the nucleophilicity of the side chain hydroxyl group of 
T206, which forms a covalent bond with the carbonyl carbon of the substrate in the 
acylation step. S72 and T224 fine tune the properties of T206. The negatively charged 
enzyme-substrate transition state is stabilized by an oxyanion hole, which is formed by 
hydrogen bonds from T257 and G258. In the deacylation step, a water molecule 
hydrolyzes the complex, the carbohydrate and aspartic acid are released and the enzyme 
is regenerated. Modified from Tikkanen et al. 1996a. 
 
4.6. The prokaryotic AGA enzyme 
The prokaryotic AGA enzyme was purified in 1993 from Flavobacterium meningosepticum 
(Tarentino and Plummer 1993) and the gene was cloned in 1995 (Tarentino et al. 1995). 
The biochemical properties of the bacterial enzyme are similar to the human counterpart.  
The bacterial AGA enzyme is also inhibited by 5-diazo-4-oxo-L-norvaline. However, the 
 specific activity is higher than in most mammalian AGAs (Tarentino and Plummer 1993). 
The periplasmic 295-amino acid bacterial AGA also contains a leader sequence and is 
synthesized as an inactive precursor which is activated autocatalytically (Tarentino et al. 
1995, Guan et al. 1998, Xu et al. 1999). The amino acid sequence is 35% identical with 
human AGA and the catalytic residues are conserved (Liu et al. 1998). The antibodies 
against the native rat liver AGA cross-reacted with the bacterial AGA (Tarentino and 
Plummer 1993). The crystal structure of the endogenous WT bacterial enzyme has been 
published (2gaw, 1ayy) (Guo et al. 1998, Xuan et al. 1998), and later the precursor form of 
the enzyme was purified (Cui et al. 1999) and the structure solved by crystallography 
(9gaa, 9gac, 9gaf) (Xu et al. 1999). Two other precursor structures were published recently 
(1p4k, 1p4v) (Qian et al. 2003). The folding of the bacterial glycosylasparaginase is very 
similar to that of the human AGA, although the sequence identity is quite low and disulfide 
bridges are not present in the bacterial enzyme (Xuan et al. 1998). In contrast to the 
human AGA, no trimming of the C-terminal parts of the subunits occurs in the bacterial 
enzyme and it is nonglycosylated. The structure reveals that the active site funnel is wider 
in the bacterial than in the human AGA enzyme, although the active site residues are 
conserved. No extensive comparisons of the substrate requirements have been reported. 
The similarity of the native enzyme and the precursor molecule provided direct evidence of 
the autocatalytic activation, since it would be very difficult for any protease to reach the 
scissile peptide bond at the bottom of the active site funnel. The autocatalytic reaction 
mechanism of bacterial AGA has also been presented (Xu et al. 1999, Qian et al. 2003) 
and the dimerization of precursor polypeptides has been analyzed (Wang and Guo 2003). 
The lower stability of the bacterial αββα-tetramer (Xuan et al. 1998) may result from 
absence of the C-terminal random coil of the human AGA, which stabilizes the molecule 
(Riikonen et al. 1995).  
 
5. Aspartylglucosaminuria (AGU) 
5.1. Clinical features and diagnosis 
The Finnish disease heritage (Perheentupa 1972), a group of rare hereditary diseases that 
are over-represented in Finland, is a consequence of the population history of Finland 
(Norio et al. 1973, Norio 2003a, 2003b). The heritage comprises at least 36 disorders, 
most of which are monogenic and autosomally recessive. The second most common of 
these diseases is aspartylglucosaminuria (AGU, OMIM 208400), a lysosomal storage 
disease, which is caused by deficient activity of AGA (Pollitt et al. 1968, Palo and Mattsson 
1970, Autio 1972, Aula et al. 2001). The causative mutations were characterized after 
isolation of the cDNA (Ikonen et al. 1991b). The lack of AGA activity causes accumulation 
of glycoasparagine (mainly AADG) in the lysosomes of all cell types (Haltia et al. 1975), 
resulting in a rather uniform phenotype with progressive mental retardation, coarse facial 
 features, and skeletal and connective tissue abnormalities (Autio et al. 1973). Abnormal 
amounts of glycoasparagines are also excreted in the urine and can be detected by thin-
layer chromatography or liquid chromatography (Pollitt et al. 1968, Sugahara et al. 1976, 
Kaartinen and Mononen 1989). The accumulation of a variety of glycoasparagines could 
result from defective α(1-6)-mannosidase activity. This enzyme only hydrolyzes substrates 
already hydrolyzed by AGA (Haeuw et al. 1994). Virtually all cell types exhibit deficient 
AGA activity (Palo et al. 1972, Maury 1980) but the central nervous system cells are most 
severely affected. In the brain, AGU primarily affects the grey-matter but delayed 
myelination in white-matter occurs (Autti et al. 1997). The developmental lifespan of the 
patients is divided into three phases. Firstly, in childhood the patients steadily learn new 
things. Secondly, in puberty learning is impaired and the patients may lose some skills and 
abilities. Thirdly, rapid mental and physical retardation occurs after the age of 25-28 years 
(Arvio and Arvio 2002). Epileptic seizures are common during the later course of the 
disease. The mean age at diagnosis is 5.5 years in Finland (Arvio et al. 1993a), the skills 
of AGU patients peak at 13-16 years, and the life expectancy is 40 and 35 years in females 
and males, respectively (Arvio et al. 1993b). The most common Finnish mutation, AGUFin 
major, manifested itself some 2000-2500 years ago (75-100 generations) and occurs 
throughout the country (Varilo et al. 1996). The linkage disequilibrium in disease alleles 
can be observed over an interval of 2 centiMorgans, reflecting the relatively old age of the 
mutation. The disease incidence in Finland is 1:16000 (Peltonen et al. 1999), and the 
carrier frequency varies from 1:132  in Southern Bothnia to 1:63 in North Karelia (Pastinen 
et al. 2001). The existence of the AGUFin major  founder mutation enables the use of rapid 
and convenient DNA methods for large-scale carrier screening: solid-phase mini-
sequencing (Syvänen et al. 1992), PCR (Nilssen et al. 1993), and DNA-chips (Pastinen et 
al. 2001). More than 260 AGU patients have been reported in Finland and over 30 
elsewhere in the world (Norio 2003c).  
 
5.2. AGU mutations 
AGU was first reported in 1968 in two English siblings (Pollitt et al. 1968). AGU is the most 
common disorder of glycoprotein metabolism with defective N-linked oligosaccharide 
breakdown. Other glycoproteinoses include α-mannosidosis (Nilssen et al. 1997), β-
mannosidosis (Alkhayat et al. 1998), and Schindler disease (Wang et al. 1990). The 
AGUFin major mutation represents 98% of all Finnish disease alleles and originated from 
one founder mutation (482G>A) which causes an amino acid replacement (C163S) in the 
AGA polypeptide (Ikonen et al. 1991b). Most of the Finnish patients are homozygotes for 
the AGUFin major allele. In vitro expression of cDNA carrying the AGUFin mutation has 
revealed that lack of correct folding and subsequent activation of the AGU polypeptide 
cause rapid intracellular degradation of the polypeptide (Ikonen et al. 1991c, Riikonen et al. 
1994). The other Finnish mutation, AGUFin minor, is a 2 bp deletion which causes a 
 frameshift and a premature stop codon in addition to reduced transcription levels (Isoniemi 
et al. 1995). Patients with this mutation are always compound heterozygotes with AGUFin 
major in the other allele. One founder mutation is responsible for all AGUFin minor alleles, 
according to haplotype data (Valkonen et al. 1999). AGU disease predisposes patients to 
chronic arthritis (Arvio et al. 1998) and AGU carriers may also be predisposed to arthritis 
(Arvio et al. 2002). A total of 18 sporadic AGU alleles have been reported outside of 
Finland (Fisher and Aronson 1991, Ikonen et al. 1991a, Yoshida et al. 1992, Park et al. 
1993, Peltola et al. 1994, Jalanko et al. 1995, Park et al. 1996a, Peltola et al. 1996, 
Laitinen et al. 1997, Coulter-Mackie 1999). All known AGU mutations are summarized in 
Figure 10. In addition, partial deletion of the 3 UTR causes AGU in one case (Ikonen et al. 
1992). The effects of AGU mutations at the polypeptide level have been reported for some 
of the mutations: AGUFin (Ikonen et al. 1991c, Enomaa et al. 1992, Riikonen et al. 1994), 
C64X (Peltola et al. 1994), S72P (Peltola et al. 1996), A101V (Park et al. 1993), L263X 
(Park et al. 1996a), S269fsX378 (Fisher and Aronson 1991), and G314fsX378 (Jalanko et 
al. 1995). However, the functional link between known molecular genetic and enzyme 
defects and changes in neuronal cell pathology has remained largely unknown for 
lysosomal storage diseases including AGU (Walkley 1998).  
 
5.3. AGU mouse model 
The mouse AGA gene structure is also known (Tenhunen et al. 1995). The 11 kb gene 
contains 9 exons and the 1.2 kb mRNA contains a 1041 bp cDNA whose sequence identity 
is 84% compared to human. The sequence identity of the mouse AGA polypeptide (also 
346 amino acids) is 84% and the polypeptide is processed into α- and β-subunits similarly 
to the human counterpart. The active site residues are well conserved. Two mouse models 
of AGU have been generated (Kaartinen et al. 1996, Jalanko et al. 1998). The phenotype 
and histopathology of the AGU mice mimic the human disease characteristics well 
(Jalanko et al. 1998, Kaartinen et al. 1998, Tenhunen et al. 1998). The latter mouse model 
has been utilized in bone-marrow transplantation (Laine et al. 1999) and gene therapy 
(Peltola et al. 1998, Harkke et al. 2003) experiments with promising results.  
 
6. N-terminal nucleophile hydrolases 
The core αββα -structure, the N-terminal nucleophile, and the topology of secondary 
elements characteristic of AGA have been found in other proteins as well (Brannigan et al. 
1995). The N-terminal nucleophile hydrolase (Ntn-hydrolase) enzyme superfamily consists 
of AGA (Oinonen et al. 1995), the β-subunit of the proteasome (Löwe et al. 1995), 
penicillin G acylase (Duggleby et al. 1995), penicillin V acylase (Suresh et al. 1999), 
glutamine phosphoribosylpyrophosphate (PRPP) amidotransferase (Smith et al. 1994), 
 glutaryl 7-aminocephalosporanic acid acylase (Lee et al. 2000), cephalosporin acylase 
(Kim et al. 2000), and glucosamine-6-phosphate synthase (Isupov et al. 1996). So far, 
AGA and the proteasome are the only mammalian members of the superfamily which have 
been characterized. The activation of the enzymes occurs autocatalytically from an inactive 
polypeptide and reveals the critical α-amino group of the catalytic residue, which is Thr, 
Ser, or Cys. The side chain of the catalytic residue, the nucleophile, catalyzes the 
hydrolysis of a substrate amido bond and each enzyme has a different substrate 
specificity. In the case of AGA, penicillin G acylase, cephalosporin acylase, and glutaryl 7-
aminocephalosporanic acid acylase activation, the precursor polypeptide chain is cleaved 
into two polypeptide subunits of the active protein, whereas in proteasome and glutamine 
PRPP amidotransferase, the activation results in the removal of a propeptide. 
 
A range of autocatalytic events proceed via protein splicing (Perler et al. 1994), where the 
initial steps are thought to involve an N->O acyl rearrangement to generate a branched 
intermediate (Shao et al. 1996). In Ntn-hydrolases, the hydrolysis of the peptide bond 
preceding the N-terminal active site residue by an autocatalytic rearrangement is similar to 
the initial step in the protein splicing pathway. The N->O acyl rearrangement reaction is 
strongly pH-dependent, favoring the ester under acidic conditions and the amide under 
alkaline conditions. In Ntn-hydrolases, it is generally believed that the catalytic nucleophile 
also acts as the autocatalytic nucleophile (Schmidtke et al. 1996, Lee and Park 1998, Li et 
al. 1999, Hewitt et al. 2000, Kim et al. 2002). Other active site residues may also have 
roles in both the catalytic and autocatalytic reactions. 
 
6.1. Proteasome β-subunit (PRO) 
The proteasome is the central enzyme of protein degradation in the cytosol and the 
nucleus (EC 3.4.25.1). It is composed of regulatory α-subunits and proteolytic β-subunits 
(PRO). The subunits are arranged as 4 rings: the outer rings contain 7 α- and the inner 
rings 7 β-subunits. The 7 PRO polypeptides are all different and only 3 of them are active 
with different substrate specificities (Dick et al. 1998). The archaebacterial (1pma) (Löwe et 
al. 1995) crystal structure of the active complex has been solved, whereas the yeast 
complex (1ryp) (Groll et al. 1997) contains mutagenized active site residues (Chains H and 
V: T1A; Chains L and Z: K33R). The 28-member complex is barrel-shaped and the active 
sites are on the inner surface. The precursor of PRO is activated by removal of the 
propeptide, which reveals the critical α-amino group of the catalytic residue, T1. For the 
autocatalytic reaction, the N-terminal amino group is not available as a proton acceptor. 
K33 has been considered to act as the general base (Schmidtke et al. 1996), although it is 
stabilized in its protonated form by three well-defined hydrogen bonds and a salt link to 
D17 in yeast (Ditzel et al. 1998). Instead, a catalytic water molecule, seen in the high-
resolution structure of three active subunits of the yeast proteasome (Groll et al. 1997), is 
 ideally positioned to act as the general base and promote the abstraction of the proton 
from the T1 hydroxyl group. This enables nucleophilic attack on the carbonyl carbon of the 
preceding peptide bond. The resulting intermediate decays to the ester, which is 
subsequently hydrolyzed to release the propeptide (Ditzel et al. 1998). The propeptide 
adopts a strained turn, the γ-turn, (Milner-White 1990) between L-2 and T1. S129 stabilizes 
the transition state during the activation, while G47 performs this role in enzyme catalysis 
(Ditzel et al. 1998).  
 
6.2. Penicillin G acylase (PGA) 
The in vivo role of the bacterial penicillin G acylase (PGA) (EC 3.5.1.11) is not yet clear, 
but the enzyme is used on an industrial scale to produce antibiotics (Bruggink et al. 1998). 
The native penicillin G acylase crystal structure from Eschericia coli has been solved 
(1pnk) (Duggleby et al. 1995), and further re-refined to 1.3 Å (1gk9) (McVey et al. 2001). 
The native enzyme is an αβ-dimer. Activation of penicillin G acylase occurs 
autocatalytically (Choi et al. 1992, Kasche et al. 1999). The precursor (1e3a) and mature 
forms of PGA have very similar structures (Hewitt et al. 2000). However, substantial 
structural differences exist in the C-terminal part of the α-chain. In the precursor, the linker 
peptide is cleaved autocatalytically between Y260 and P261 by Oγ of T262 according to 
dynamic simulation. The catalytic residue, S264, has two well-defined conformations that 
can be correlated to the presence or absence of the linker peptide. The same residues that 
maintain the tetrahedral intermediate in the active enzyme are also suggested to be 
responsible for the stabilization of the autocatalytically generated intermediate of precursor 
activation. However, the B-factors of the residues at the processing site are high and the 
stereochemistry at this site may differ from that of the mature enzyme (Hewitt et al. 2000). 
The peptide bond between residues G263 and S264 of the mutant precursor shows non-
ideal stereochemistry and is consistent with partial cleavage, disorder or distortion of this 
bond. The three residues preceding the nucleophile are important for efficient processing 
of the precursor (Choi et al. 1992). R526 is crucial for efficient processing and stabilization 
of the oxyanion hole (Alkema et al. 2002), confirming that an intact oxyanion hole is 
necessary for efficient processing of the precursor enzyme (Alkema et al. 2000). 
 
Penicillin V acylase (PVA) and penicillin G acylase (PGA) have similar substrates, but their 
molecular properties are different. PVA from Bacillus sphaericus (2pva, 3pva) is tetrameric, 
while PGA from E. coli is a heterodimer. The enzymes have no sequence similarity. They 
share the αββα-structural core but are otherwise unrelated in primary sequence, including 
the active site residue (Duggleby et al. 1995, Suresh et al. 1999). 
 
 6.3. Glutamine amidotransferase (GAT) 
Glutamine 5-phosphoribosyl-1-pyrophosphate amidotransferase (EC 2.4.2.14) catalyzes 
the initial reaction in de novo purine nucleotide biosynthesis and is the key regulatory 
enzyme in the pathway. The tetrameric native enzyme from Bacillus subtilis contains two 
structural domains: an N-terminal glutaminase domain (GAT) and a C-terminal 
phosphoribosylamine-synthesizing domain (1gph) (Smith et al. 1994). The GAT domain 
belongs to the Ntn superfamily and is activated by propeptide removal. The functional 
residues of the E. coli GAT include the nucleophile (C1), the oxyanion hole (N101 and 
G102), substrate binding (R73 and D127), and interdomain coupling (Y74) (Kim et al. 
1996). Mutational analysis of B. subtilis GAT (1ecf) (Muchmore et al. 1998) showed that 
the propeptide was not processed after replacement of the nucleophile or two residues of 
the oxyanion hole (Li et al. 1999). The results suggest that the oxyanion hole which 
participates in catalysis also has a role in propeptide processing, possibly by stabilizing the 
tetrahedral intermediate resulting from a nucleophilic attack of C1 thiolate on the peptide 
bond between E-1 and C1. A general acid or base is also needed for propeptide cleavage. 
The α-amino group of C1 is in peptide linkage and is therefore unavailable to assume this 
function. For this purpose, mutagenesis of conserved histidine residues was performed 
and the results revealed that H70 was necessary to maintain propeptide processing (Li et 
al. 1999). However, no direct role for H70 could be assigned. In addition, mutant 
polypeptides carrying several replacements of E-2 and a double mutant of residues E-2/E-
1 were partially processed. The interpretation of these results leads to the conclusion that 
some of the residues needed for enzymatic catalysis are involved in propeptide 
processing. In the active site of the mature E. coli enzyme, the oxyanion hole residues and 
C1 are hydrogen-bonded to the same water molecule (Muchmore et al. 1998). 
 
6.4. Other members of the superfamily 
Other Ntn-hydrolases include glutaryl 7-aminocephalosporanic acid acylase (EC 3.5.1.11) 
(Lee et al. 2000) and cephalosporin acylase (3.5.1.11) (Kim et al. 2000), which have an N-
terminal serine in the β-subunit. The enzymes are functionally related to PGA and the 
active sites are structurally similar. However, the enzymes have different substrates (Fritz-
Wolf et al. 2002). Cephalosporin acylase (CA) catalytic amino acids have been 
characterized (Kim and Kim 2001). The active αβ-heterodimeric molecule (1fm2) (Kim et 
al. 2000) and the precursor molecule from Pseudomonas diminuta have very similar 
structures (1keh) (Kim et al. 2002). Both structures contain two water molecules, which 
assist S1β in carrying out the nucleophilic attack in intramolecular activation of the 
precursor. The role of the second water molecule has been suggested to be stabilization of 
the reaction intermediate (oxyanion hole), while the first water molecule acts as a general 
 acid and base. The first water molecule is bound by four hydrogen bonds in 
pseudotetrahedral geometry (Kim et al. 2002).  
 
The analysis of the activation mechanism of glutaryl 7-aminocephalosporanic acid acylase 
(GCA) from Pseudomonas revealed that S199 is essential for catalysis and intramolecular 
autocatalysis (Lee and Park 1998). Subsequently, the precursor is cut in another location 
as well, probably by the activated S199 of the other active site of the (αβ)2 heterotetrameric 
molecule. The crystal structures of the native (1or0) and the precursor (1oqz) form have 
been solved but are not released until in March 2004 (Kim et al. 2003). Dimerization of the 
GCA precursors sequesters a slightly larger surface area than in the WT molecule. The 
interaction between the precursor monomers is based on van der Waals interactions, 
hydrogen bonds, and salt bridges formed by conserved residues. Dimerization may be 
guided by electrostatic repulsion of surface patches which exhibit negative potential on the 
precursor. The structure of the linker peptide between the α- and β-subunits reveals 
significant differences between the CA and GCA, although the sequences are identical. 
The CA spacer peptide shows a bend conformation, whereas GCA contains α-helical and 
β-strand conformation. The substrate binding cavity is shielded by the spacer peptide. 
After the autocatalytic activation, the nucleophile, S170, at the N-terminus of the β-subunit 
is exposed to the solvent and the α-amino and side chain groups are hydrogen-bonded to 
a water molecule. Another water molecule is also trapped in a hydrophobic environment. A 
reaction mechanism for the activation of the precursor is also suggested. The trapped 
water molecules may play important roles in the activation. 
 
6.5. Autoproteolytic activation of other proteins 
Intramolecular autoproteolysis has also been suggested by kinetic analysis for the first 
processing step in the activation of non-Ntn-hydrolases such as calpain (Zimmerman and 
Schlaepfer 1991), papain (Vernet et al. 1991), pepsin (Bustin and Conway-Jacobs 1971), 
mouse prohormone convertase (Goodman and Gorman 1994), and thrombin proenzymes 
(Petrovan et al. 1998), and the maturation of hedgehog (Lee et al. 1994, Hall et al. 1997) 
and viral (McCann et al. 1994, Zlotnick et al. 1994, Wu et al. 1998) proteins. The folding of 
the bacterial serine protease subtilisin is dependent on its prosegment, which is 
autocatalytically cleaved to give the mature enzyme (Gallagher et al. 1995). The biological 
role of the prosegment is to provide a folding pathway, acting as an intramolecular folding 
guide. In addition, the activation of inteins occurs autocatalytically (Perler et al. 1997). The 
ester intermediate captured during the activation of aspartate decarboxylase provides 
evidence of an N->O acyl shift (Albert et al. 1998). 
 AIMS OF THE PRESENT STUDY 
This study was carried out in order to characterize in detail the activation process of the 
human AGA. This knowledge is essential in order to define the detailed cellular 
consequences of various AGU mutations at the cellular level. To elucidate the disease-
causing mechanism of AGU, the consequences of different AGU mutations were also 
monitored. Finally, the precursor molecule of AGA was expressed and purified in order to 
solve its three-dimensional crystal structure. 
 
The specific aims of this study were: 
 
1. To characterize the autocatalytic activation mechanism of AGA by in vitro 
expression studies. 
 
2. To identify the amino acids that contribute to the oligomerization of the precursor 
molecules in the ER. 
 
3. To characterize the consequences of known AGU mutations by in vitro expression 
studies. 
 
4. To express and purify the AGA precursor molecule for structural determination 
experiments. 
 
 MATERIALS AND METHODS 
Material or method Original publication
Patients II 
Genotyping II 
DNA extraction and sequencing I, II, III 
In vitro site-directed mutagenesis I, II, III 
Mutation analysis I, II, III 
Cell culture I, II, III 
Transfections I, II, III 
Metabolic labelling I, II, III 
Immunoprecipitation I, II, III 
Gel electrophoresis I, II, III 
Endoglycosidase H digestion I 
Gel filtration I, III 
Immunofluorescence microscopy II, III 
Assay for AGA activity I, II, III 
Determination of protein concentration I, II, III 
Kinetic measurements III 
 
Table 1. Materials and methods used in this study. 
7. Stable expression of AGA in CHO cells (I) 
Chinese hamster ovary cells (CCL61, ATCC) were maintained in DMEM supplemented 
with 10% fetal calf serum and antibiotics and co-transfected with mutagenized AGA cDNA 
in SV-poly and pCI-neo expression vector (Promega), using the lipofectamin method as 
suggested by the manufacturer (Life Technologies). Forty-eight hours post transfection the 
cells were plated with medium containing 500 µg/ml Geneticin (G418, Gibco). After 14-20 
days, colonies resistant to G418 were selected and cloned by limited dilution and the 
clones with the highest AGA activity were selected for further analyses. 
8. Production of the yeast cell line for AGA precursor expression 
Production of the cell line was performed with the Pichia Expression Kit, as suggested by 
the manufacturer (Invitrogen). The AGA cDNA was mutagenized (D205G+T206A) and 
cloned into the pPIC3.5K expression vector, which allows multiple tandem integrations of 
the target gene in the Pichia genome using homologous recombination. The target gene is 
under the control of the alcohol oxidase promoter, which can be induced with methanol. 
The vector was transformed into TOP10F bacterial cells and AGA-containing clones were 
identified with PCR. Plasmid DNA was extracted from a clone and the sequence was 
confirmed. The plasmid DNA was digested separately with SacI and SalI restriction 
enzymes for insertion at the alcohol oxidase 1 gene and the histidinol dehydrogenase 
gene, respectively, and purified by phenol extraction. The DNA was then transformed into 
two His- (histidine-synthesis-deficient) yeast cell lines (KM71 and GS115), using 
 electroporation. The cells were plated and His+ transformants were selected. Next the 
clones were screened for Mut+ (methanol utilization fast, GS115) and MutS (methanol 
utilization slow, KM71) transformants. To screen for multiple inserts, the transformants 
were plated on YPD-G418 plates containing increasing concentrations of the neomysin 
analog G418, against which the vector confers resistance. All G418 resistant clones were 
picked and purified and the level of G418 resistance was confirmed. Five clones were 
incubated on methanol-containing plates to promote AGA precursor expression and the 
AGA expression level was determined. Two clones were chosen for expression and partial 
purification on a larger scale. Finally, one clone with a 3.0 mg/ml resistance to G418 was 
chosen for AGA precursor production (GS115 with multiple copies of the AGA gene 
integrated into the alcohol oxidase 1 gene).  
9. Expression, purification, and analyses of AGA precursor 
The chosen clone expressed AGA precursor approximately at the level of 14 mg/l and 
secreted AGA into the culture medium using the signal sequence of AGA for targeting to 
the secretory pathway. The AGA expression was carried out at +30oC in a shaking 
incubator at 200 rpm. The yeast was first grown to a suitable density in buffered methanol 
complex medium over four nights. For protein expression, the medium was changed to 
buffered minimal methanol medium supplemented with 1 mM EDTA (to inhibit 
metalloproteases) and regular additions of methanol (to promote expression). In addition, 
10 mM glycine was added to stabilize the AGA precursor (Cui et al. 1999, Xu et al. 1999). 
The cell culture medium was collected and frozen. Using tangential flow filtration (Mini 
Ultrasette, Filtron Technology Corporation) the medium was concentrated and the buffer 
changed to buffer suitable for hydrophobic interaction chromatography. Protease inhibitor 
cocktail (Sigma) was added and the buffer was exchanged for each of the purification 
steps, using microconcentrators (Centriprep and Centricon, Amicon). Precursor purification 
was performed using liquid chromatography on a FPLC system (Merck Hitachi) with 
Pharmacia columns (Amersham Biosciences) at +20oC with ice-cold buffers to minimize 
AGA precursor cleavage into abnormal subunits. Hydrophobic interaction chromatography 
was performed on a 5 ml Octyl Sepharose 4 Fast Flow column. Anion exchange 
chromatography was performed using two MonoQ HR 5/5 columns connected in series. 
Gel filtration chromatography was performed using a Superdex 200 HR 10/30 column and 
finally cation exchange chromatography was performed on two MonoS HR 5/5 columns 
connected in series. Proteins on SDS-PAGE were visualized using Coomassie Brilliant 
Blue R250 staining (Amersham Biosciences), Sypro Red fluorescent gel staining (FMC), 
silver staining (SilverXpress, Invitrogen), western blotting, or enhanced 
chemiluminescence. The purity and properties of the AGA precursor preparation were 
analyzed using 2-dimensional SDS-PAGE at pH 4-7 (IGPphor, Amersham Biosciences). A 
mass spectrometric analysis of the preparation was performed at Viikki Biocenter, using an 
ESI-quadrupoltime-of-flight instrument (Q-TOF1, Micromass).  
 RESULTS AND DISCUSSION 
Due to extensive characterization of human AGA, it has become one of the best-
characterized lysosomal enzymes. The intracellular processing, structure, catalytic 
mechanism, and transport of AGA have been analyzed in detail. However, only preliminary 
data of the initial events which occur in the ER, including AGA activation and dimerization 
of precursor molecules, had been obtained prior to this study. This study also elucidates 
the consequences of patient mutations in detail.  
 
10. Analysis of conserved residues of the AGA molecule 
Based on the information of the 3D-structure of human AGA, conservation of the residues 
of the active site, lysosomal targeting, and glycosylation of asparaginases and 
glycoasparaginases among 10 species were analyzed. The important residues, regarding 
the AGA enzyme activity, were found to be conserved from bacteria to mammals. This 
alignment revealed only 12% overall sequence identity (33/275 residues) and without the 
plant asparaginases, the sequence identity rose to 26% (71/278). The human AGA 
sequence is shown in Figure 6. Based on the alignment, two clusters of amino acids 
showed high conservation in the three-dimensional structure of the native human AGA. 
One of these regions was located on the interface between the two αβ-dimers, and another 
on the active site area, implying functionally essential roles for these areas of the molecule. 
These regions were selected as targets of in vitro mutagenesis followed by functional 
analysis of the mutated polypeptides. As a general practice, the replacing residues were 
chosen to be of equal size or smaller than the original residue so that the packing of the 
molecule should not be disturbed. This practice was not followed with some replacements 
at the dimer interface, where a bulkier side chain was introduced in order to study whether 
a residue occupying more space affects the dimerization of precursor polypeptides. Where 
needed, corresponding bacterial amino acids are shown in parentheses. 
 
  
Figure 6. The human AGA amino acid sequence. The residues conserved from plants to 
mammals are shaded in grey, the locations of patient mutations are bold underlined, and 
locations of the secondary structure elements are shown above the sequence. The 
secondary structure elements conserved in Ntn-hydrolases are boxed. 
 
10.1. Dimerization of the precursor molecules (I, II) 
Dimerization of AGA precursors occurs post-translationally in the ER and is a prerequisite 
for AGA activation. The precursor molecules are autocatalytically cleaved into the N-
terminal α- (27 kDa) and C-terminal β- (17 kDa) subunits (Ikonen et al. 1993, Riikonen et 
al. 1995) thus forming the active tetrameric molecule. The dimer interface of AGA is a 
relatively wide area containing a number of hydrophobic residues. In the 3D-structure, the 
interface is quite flat except for one clear protrusion of a loop that penetrates into the other 
αβ-dimer of the native enzyme. In this loop region, H124 is completely conserved and 
T125 is conserved in mammals. Two substitutions were found to affect the dimerization of 
AGA, namely H124R and H124W. Due to a processing failure, these mutants produced 
only the non-processed precursor polypeptide, which was secreted into the culture medium 
and thus no enzyme activity beyond the background level was detected. Both of these 
substitutions affected the dimerization of the precursor molecules and both dimeric and 
monomeric precursor could be observed after gel filtration. The large side chain of arginine 
or tryptophan obviously did not fit properly into the narrow gap between the two precursor 
molecules. When labelled with [35S]Cys and [32P]Pi the oligosaccharides of mutant 
precursors were found to be normally phosphorylated. This would suggest that these 
substitutions do not result in severe misfolding of AGA in the ER, since only correct 
positioning of the three phosphotransferase recognition regions results in phosphorylation 
of the oligosaccharides of AGA (Tikkanen et al. 1997). Correct folding is further supported 
by the fact that the most common mutation causing aspartylglucosaminuria, AGUFin, 
 prevents the correct folding of the C-terminal end of the α-subunit (Ikonen et al. 1991c, 
Oinonen et al. 1995), and the mutant polypeptides are not phosphorylated in vitro and 
remain monomeric (Peltola et al. 1996). In addition, severely misfolded AGA polypeptides 
can only be immunoprecipitated after the samples have been denatured by boiling and 
subsequently using antibodies against the denatured subunits (Tikkanen et al. 1995). 
Immunofluorescence analysis of cells expressing H124R and H124W mutants revealed 
staining of the Golgi and ER, implying that even at steady state, the mutant AGA 
polypeptides were not found in lysosomes. Western blotting, using antibodies against 
denatured subunits of AGA, further demonstrated that a small quantity of degradation 
products existed intracellularly, suggesting instability of the AGA polypeptides carrying 
these substitutions.  
 
In conclusion, H124 seems to be crucial for the correct packing of the two precursor 
polypeptides against each other, as suggested by the crystal structure. Substitutions for 
T125 did not have any effect on the dimerization but partial misfolding and misprocessing 
was observed. To exclude the effect of over-expression on the results obtained, stable 
CHO cell lines producing the H124R mutant AGA polypeptides were constructed. The 
findings in the stable expression system confirmed the results obtained with transient 
expression in COS-1 cells. 
 
Three patient mutations, G100E, A101V, and F135S, reside on or near the interface 
between the two αβ-dimers of AGA and were found to affect the dimerization of AGA. The 
structural environment of F135 is hydrophobic and substitution of F135 for hydrophilic 
serine eliminates the local stabilizing van der Waals interactions. The delayed activation 
seen in biochemical experiments probably results from impaired dimerization in the ER, 
caused by the lack of stabilizing interactions between the two precursor polypeptides. 
G100E and A101V substitutions disturb the 3D-structure of AGA because of space 
restrictions and probably also because the local structure around H124 becomes distorted.  
 
Among the patient mutations, P268fsX319, S269fsX274, G314fsX378, and E334X 
produced more stable polypeptides than C306R or L263X. This indicates that residues 
D261 to L267 might be important for polypeptide folding and stability. This hypothesis is 
supported by the AGA structure: these amino acids, like H124, are located between the 
αβ-dimers of AGA and therefore might stabilize the interaction between two αβ-dimers in 
the molecule. In addition, Riikonen et al. (1996) showed that the large loop structure 
consisting of the C-terminal part of the α-subunit is crucial for dimerization. Figure 7 shows 
the most critical regions at the dimer interface. 
 
The dimerization of bacterial AGA has also been analyzed (Wang and Guo 2003). Some 
conserved residues at the dimer interface, V128, Ile240, E274, and R292 (V105, I186, 
 E220, and R238), were found to affect the dimerization. These residues are largely buried 
in the dimer but would be exposed in a monomer and their mutagenesis changes the 
quaternary structure of the molecule. Previously, Ile240 was found to be essential for 
human AGA precursor dimerization (Riikonen et al. 1996). A two-step dimerization is 
suggested to trigger bacterial AGA activation (Wang and Guo 2003). In the first step, the 
folded precursors dimerize through an extensive hydrophobic surface. In the second step, 
the dimer interface is modified and the dimers interact more strongly, while a 
conformational strain is created at the activation site. As a result, autoproteolysis is 
triggered to remove the strain of the polypeptide backbone and generate the N-terminal 
threonine.  
 
 
 
Figure 7. The three-dimensional structure of the native human AGA enzyme. One half of 
the AGA molecule, comprising one α- and one β-subunit, is red and green and the other is 
blue. Three regions in both αβ-dimers provide an abundance of contacts between the two 
αβ-dimers of AGA: Firstly, the loop containing residue H124 (cyan); secondly, the amino 
acids in the α-helix BH1 and the following loop (yellow); thirdly, the large loop structure at 
the C-terminal end of the α-subunit (white).  
 10.2. Autoproteolysis of the precursor molecules (I, III) 
Autocatalytic activation of AGA is dependent on correct folding and dimerization of 
precursor polypeptides. This imposes strict structural requirements for the precursor 
molecules. Thus even missense mutations of the AGA gene often result in severe 
problems of activation. Prior to this study, activation of the human AGA precursor had been 
prevented with active site amino acid replacements (Ikonen et al. 1993, Riikonen et al. 
1995, Peltola et al. 1996, Tikkanen et al. 1996a). The human AGA crystal structure implied 
that the activation should occur autocatalytically, since the activation site was located in 
the bottom of the funnel-shaped active site (Oinonen et al. 1995). Additionally, some data 
on endogenous bacterial AGA activation had been obtained (Guan et al. 1996). In this 
study, the residues of the activation site were first replaced, using site-directed in vitro 
mutagenesis (I, 1998). Later, residues surrounding the active site were chosen as targets 
for mutagenesis (III, 2003). Between these studies, the bacterial AGA was characterized 
using mutagenesis (Guan et al. 1998, Liu et al. 1998), and the bacterial AGA WT and 
precursor crystal structures were published (Guo et al. 1998, Xu et al. 1999).  
 
10.2.1. Residues participating in autocatalysis (I) 
During the autocatalytic activation of AGA, the peptide bond between D205 and T206 is 
cleaved. At this activation site, three residues were mutagenized: H204 and D205 before 
the cleavage site and the N-terminal nucleophile T206 immediately after the cleaved bond. 
Among the mutations at the activation site, only H204G and H204S were partially 
activated. Other mutations of H204, D205, or T206 totally prevented the activation 
cleavage. The dimerization of the precursors was not affected by any of the activation site 
mutations. Apparently, the polypeptides were correctly folded, since they were transported 
to the lysosomes, where the precursor was processed into α- and pro-β-subunits. 
Additionally, the cells efficiently secreted precursor polypeptide into the culture medium. 
Similar processing has been reported with substitutions for amino acids R234 and T257 
(Tikkanen et al. 1996a). To exclude the effect of over-expression on the results obtained, 
stable CHO cell lines producing T206C mutant AGA polypeptides were constructed. The 
findings in the stable expression system confirmed the results obtained by transient 
expression in COS-1 cells. 
 
The sequence H204-D205-T206 at the proteolytic activation site is conserved in the 
currently known glycoasparaginases or asparaginases except in plants. The lack of 
complete conservation would suggest that the side chains of the residues before the 
cleavage point do not directly participate in the autocatalytic activation in 
(glyco)asparaginases. Guan et al. (1996, 1998) suggested that H204 (H150) would be 
necessary for initiation of the nucleophilic attack resulting in the activation of bacterial 
 AGA. In contrast, the results suggest that H204 is not absolutely required for the cleavage 
reaction, since H204G and H204S mutant precursor polypeptides were activated to some 
extent. Moreover, the H204S precursor polypeptide has been demonstrated to be cleaved, 
probably autocatalytically, in the medium (Peltola et al. 1996) irrespective of serum or 
protease inhibitors. 
 
The results show that D205 and T206 are essential for AGA activation and substitutions of 
these amino acids systematically result in the processing failure described above. In 
contrast to previous studies (Fisher et al. 1993, Guan et al. 1996), the results demonstrate 
that T206 (T152) is required for the actual proteolytic activation of the precursor 
polypeptide, in addition to its role in the catalytic activity of AGA (Oinonen et al. 1995). 
When T206 of human AGA was replaced by serine, activation cleavage occurred, but the 
mutant enzyme was inactive (Riikonen et al. 1995), indicating that the hydroxyl group of 
the T206 or S206 side chain is actually required for activation. Only with threonine at the 
N-terminus is this hydroxyl group in the correct position for enzymatic catalysis in 
glycoasparagine breakdown. 
 
During activation, the tetrahedral transition state of AGA (Figures 9b and 9e) may be 
stabilized by one or two hydrogen bonds, the so-called oxyanion hole. In Ntn-hydrolases, 
several oxyanion hole-forming residues have been proposed (Schmidtke et al. 1996, Ditzel 
et al. 1998, Li et al. 1999, Xu et al. 1999, Hewitt et al. 2000, Kim et al. 2002, Kim et al. 
2003). For the activation, an oxyanion hole is required in both the acylation and 
deacylation steps. In bacterial precursor AGA, T224 (T170) may stabilize the reaction 
transition state by forming the oxyanion hole during activation (Figures 9b and 9e) (Xu et 
al. 1999). Previous studies of human AGA suggest that a hydroxyl group at T224 is 
important for autoproteolysis (Tikkanen et al. 1996a) and thus T224 may stabilize the 
reaction transition state by forming the oxyanion hole. However, as the precursor 
structures of bacterial AGA differ at the scissile D205-T206 peptide bond, it is unclear 
whether T224 truly stabilizes the reaction intermediate or whether it only stabilizes the 
active site structure.  
 
10.2.2. Human versus bacterial AGA precursor 
The 3D-crystal structure of the human AGA precursor has not been solved so far. 
However, the existing bacterial AGA precursor structures from the endogenous F. 
meningosepticum enzyme (9gaa, 9gac, 9gaf) (Xu et al. 1999), (1p4k, 1p4v) (Qian et al. 
2003) have provided some clues about the structure of the human AGA precursor and 
details of the activation mechanism. The WT human (1apy) and bacterial (2gaw) molecules 
have similar structures (rmsd = 1.12 Å for the backbone of 509 residues) and the residues 
involved in enzymatic catalysis are conserved. Furthermore, the secondary and tertiary 
 structures of the bacterial mature AGA (2gaw) (Guo et al. 1998) and precursor AGA (9gaf) 
(Xu et al. 1999) are essentially identical (rmsd = 0.58 Å for the backbone of 547 residues). 
Thus, it is conceivable that the precursor structures of human and bacterial AGA are 
closely related. Consequently, the activation mechanisms are likely to be similar. 
 
The activation of the AGA precursor and enzymatic catalysis seem to be accomplished by 
the same amino acids, which makes the interpretation of experimental data complicated. 
The previous results on human (I) and bacterial (Guan et al. 1998) AGA autocatalysis 
indicate that the mechanism is less efficient than in enzymatic catalysis. Consequently, the 
analysis of the autocatalytic mechanism using mutagenesis is challenging and the results 
obtained less accurate. Furthermore, no structural (or other direct) information about the 
reaction intermediate in Ntn-hydrolase autoproteolysis studies has been obtained. The 
bacterial AGA precursor structures are very similar except at the linker peptide between 
the subunits and some neighboring residues of the active site. The nucleophile location 
and rotamer conformation vary only slightly, but the position and conformation of the 
preceding residues, including D205, are quite dissimilar. Therefore, to draw detailed 
conclusions about the residues participating at each activation step would be speculative. 
Overall, the active site of the bacterial AGA is somewhat wider than the human 
counterpart. The bacterial enzyme is periplasmic, whereas the human AGA functions in the 
acidic lysosomes. The human enzyme may have evolved to obtain a different pH optimum 
which could explain the differences. 
 
10.2.3. Residues with a structural role (III) 
The previously published human AGA mutations were evaluated to study whether they 
could potentially affect the autocatalytic activation and to enhance the structure-function 
understanding of AGA. In addition, nine novel mutations (T33A, D70A, D200A, D201A, 
N225A, G226A, K230A, S238A, and G258A) were generated, based on their location in 
the active site. The effect of the mutations was monitored by immunoprecipitation- and 
immunofluorescence-based analysis of the expressed polypeptides, and the enzymatic 
activity and kinetic parameters of AGA were measured. Table 2 summarizes the data. 
 
In the following, only the most interesting structural residues are discussed. Structural 
comparison of four Ntn-hydrolases has revealed nine fully conserved secondary structure 
elements (Oinonen and Rouvinen 2000), all located in the β-subunit of the active AGA 
molecule (Figure 6). In addition to the AGAs of various species (human AGA, 1apy), G258 
is also conserved in PRO and GAT, while PGA has alanine at the position. At the position 
corresponding to G226, only hydrophobic residues are found in other Ntn-hydrolases, 
while G226 is fully conserved in the AGAs of several species (II). 
 
 Residues G258 and T257 form the human AGA oxyanion hole that is utilized in the 
stabilization of the negatively charged carbonyl oxygen on the transition state during 
enzyme catalysis (Figure 5). G258A prevented activation and the precursor polypeptide 
existed in cells in dimeric and monomeric forms. The results indicate that G258 plays a 
crucial structural role in the activation of the human AGA precursor. The mutant 
polypeptides are probably unable to fold correctly and are mostly retained in the ER.  
 
G226 resides in a loop at the active site and the substituting aspartate disturbs local folding 
by eliminating a tight turn of the loop and presenting a larger side chain in the aqueous 
environment of the substrate-binding funnel. The G226A polypeptides showed a severe 
folding defect. The main chain nitrogen of G226 (G172) is hydrogen-bonded with the side 
chain of T224 (T170) in the human and bacterial AGA structures. The side chain of D226 
or A226 would create clashes. Possibly, the aspartate side chain could stabilize the 
structure by creating electrostatic interactions with K230. A lack of such stabilization would 
create a major folding defect like that observed in the G226A mutant. 
 
Previous data exist for additional mutations, some resulting in human AGU. The hydrogen 
bond between S72 and T206 is required for efficient enzymatic catalysis (Tikkanen et al. 
1996a). S72P mutant precursor polypeptides, found in AGU patients (Peltola et al. 1996), 
are not activated intracellularly owing to disturbed packing caused by a change in a loop 
structure at the active site. 
 
T257A (Tikkanen et al. 1996a) and the AGU-causing T257I mutant prevent activation of 
the precursor. However, the mutagenesis results of T257 are different between human and 
bacterial AGA (Tikkanen et al. 1996a, Liu et al. 1998), possibly reflecting different catalytic 
roles in the enzymes. In some bacterial precursor AGA structures (9gac and 9gaa), T257 
(T203) is hydrogen-bonded to the side chain of D205 (D151), while in others (9gaf, 1p4k, 
and 1p4v) the side chain orientation of D205 is different. The Cα-position (~1 Å) and 
rotamer conformation of T257 also vary. Thus it can not be concluded with certainty that 
the role of human AGA T257 is to properly orient the side chain D205 with a hydrogen 
bond. Figure 8 summarizes the roles of all the residues studied. 
 
  
  
 
 
Figure 8. The autocatalytic residues in the WT AGA structure. A) The polypeptide 
backbone. To show all the residues substituted, D205, H204, G203, R202, D201, and 
D200 have been built, without energy minimization into an α-helix in this figure. 
Conformation of the backbone and the side chains of these residues do not correspond to 
any AGA precursor structure. Native AGA residues are unaffected by the added residues. 
B) The WT side chains of the residues that affect autocatalysis are shown. T206 is the key 
residue in enzyme catalysis and the autocatalytic activation. D205 and possibly H204 
provide conformational strain at the activation site which may trigger autocatalytic 
activation. T224 and G258 are important structural residues. The other residues, shown in 
yellow, affect autocatalysis by providing a structural scaffold for the participating residues. 
 
10.2.4. Peptide bond distortion (I) 
Inteins are typical protein structures capable of self-splicing (Perler et al. 1994). The 
structure of the N-terminal cleavage site in the GyrA intein (Klabunde et al. 1998) revealed 
that the polypeptide backbone at the cleavage site was strained because of an 
energetically unfavorable cis-peptide bond. Although Ntn-hydrolases are not related to 
inteins, the autocatalytic peptide bond cleavage mechanisms have similarities. In AGA, 
substitutions of the fully conserved residue T206 hindered the processing, suggesting that 
the side chain of T206 would directly participate in catalysis. Substitutions of the less 
conserved D205 prevented the processing as well. This could indicate that the proper 
geometry of D205 would be essential for the autoproteolysis. In line with this observation, 
H204 could affect the geometry and activation but less efficiently than D205 does. Thus, 
 prior to the first publication among Ntn-hydrolases to show conformational strain at the 
autoproteolytic site (Ditzel et al. 1998), AGA precursor activation was proposed to be 
dependent on strain of the polypeptide backbone. 
 
In contrast to the GyrA structure, some bacterial AGA precursor structures contain a high 
energy distorted trans peptide bond between D205 (D151) and the nucleophile T206 
(T152) (Xu et al. 1999). These residues involved in the N->O acyl rearrangement form an 
unusual tight turn. The main chain distortions could raise the energy level of the activation 
site and generate the activation potential for autoproteolytic cleavage (Xu et al. 1999). The 
dimerization of AGA precursors may create polypeptide backbone strain near the scissile 
peptide bond. As a result, autoproteolysis may be triggered to remove the strain and 
generate the essential N-terminal threonine (Wang and Guo 2003). Strained splicing 
junctions are also involved in protein splicing of PI-SceI, which is processed at two 
distorted trans peptide bonds (Poland et al. 2000). Much like the GyrA structure, there 
does not appear to be a good general base in close proximity to C1 at the N-terminal splice 
junction. 
 
Among the Ntn-hydrolases PRO, GAT, PGA, CA, and GCA, the immediate N-terminal 
residue of autoproteolytic residue is glycine. The AGA sequence at the processing site is 
His-Asp-Thr except in plants where it is Ile-Gly-Thr. In addition, inteins (Perler et al. 1994), 
aspartate decarboxylase (Albert et al. 1998), and hedgehog protein (Hall et al. 1997) have 
a conserved glycine at the scissile peptide bond. PRO adopts a well-defined γ-turn 
conformation at the autoproteolytic site (Ditzel et al. 1998). The spacer peptide also 
contains conformational strain on the precursor polypeptide of GCA (Kim et al. 2003) and 
CA (Kim et al. 2002) and high-energy state of the spacer peptide has been proposed to 
trigger the autoproteolytic cleavage in GCA. In addition, the PGA precursor structure 
indicates non-ideal stereochemistry of the scissile peptide bond (Hewitt et al. 2000). Thus 
although several similarities (overall topology, similar active site residues, conformational 
strain) exist in Ntn-hydrolase activation, the details of the mechanisms probably diverge, 
possibly even within the (glyco)asparaginases. 
 
10.2.5. Activation mechanism of human AGA (I, III) 
Different bacterial precursor mutants display surprisingly different structures (Xu et al. 
1999, Qian et al. 2003). Backbone and side chain conformation of the residues in the linker 
peptide between the α- and β-subunits, including D205 (D151), and some active site 
residues differ significantly between the structures. Therefore, conclusion of the exact role 
of individual residues at each step of human AGA activation is not possible. As a 
consequence, the bacterial AGA activation mechanism (Xu et al. 1999), which was 
concluded from the data obtained from three different structures (9gaa, 9gac, 9gaf), may 
 not represent the best model for human AGA activation. This fact and the human AGA 
experimental data suggest that the activation mechanism proposed for human AGA (I) 
remains a valid reaction mechanism for human AGA autoproteolysis. 
 
According to the activation mechanism (Figure 9), the side chain of T206 would play an 
active role in the processing of AGA. The nucleophilicity of T206 is enhanced by a general 
base, which is either the side chain of D205 or a water molecule, as discussed later. Thus 
the general base has a key role in initiating the N->O acyl shift. During the acylation step, 
the side chain hydroxyl group of T206 forms a hydrogen bond with the carbonyl carbon of 
D205, and a tetrahedral intermediate is formed. The intermediate is probably stabilized an 
oxyanion hole. During the deacylation step, a neighboring water molecule probably 
hydrolyses the ester bond resulting from the N->O shift and resolves the α- and β-subunits 
of AGA. At this instant, the α-amino and side chain hydroxyl groups of T206 are ready for 
enzymatic catalysis. This reaction mechanism would require the existence of one base and 
one acid that assist in the reaction. Unfortunately, without human precursor structure the 
general base has not been identified in human AGA. Most of the active site residues 
analyzed do not appear to have a distinct role in the autoproteolytic activation reaction 
although they are important for the reaction. They surround the active site and form the 
necessary hydrogen bond network to position and interact correctly with the residues that 
participate in the reaction. 
 
 
 
Figure 9. The autocatalytic mechanism of human AGA. The activation is initiated by a 
general base (A), which receives the hydrogen atom from the side chain of T206 thus 
enabling a nucleophilic attack on the carbonyl carbon of D205 and resulting in a tetrahedral 
intermediate (B). C) An N->O acyl shift occurs and a general acid donates a proton to 
newly formed amino group terminal of T206. D) A water molecule hydrolyses the resulting 
ester bond and a second tetrahedral intermediate is formed (E). F) The intermediate is 
resolved and T206 with free amino and side chain groups is ready for enzymatic catalysis. 
 
 10.2.6. Autocatalytic activation in Ntn-hydrolases 
With T1 as the nucleophile in proteasomal enzyme catalysis, a proton acceptor in the 
active site is required for activation of the hydroxyl group. A catalytic water molecule, seen 
in the high-resolution structure of yeast PRO (Groll et al. 1997), probably acts as the  
general base to help activate the T1 hydroxyl group. Several reports of Ntn-hydrolase 
precursor structures indicate a water molecule as the general base (Ditzel et al. 1998, Kim 
et al. 2002, Kim et al. 2003, Yoon et al. 2003). An acid and a base are also required for the 
autoproteolytic activation of the AGA precursor (Figure 9). In the case of bacterial 
precursor AGA, D205 (D151) was proposed to act as the general base that was hydrogen-
bonded to the nucleophile in one precursor structure (9gaf). As discussed earlier, the 
position and conformation of D205 varies with different bacterial AGA precursor mutants. 
Thus, it is possible that also for human AGA the general base may be a water molecule. In 
the WT human AGA structure (Oinonen et al. 1995), the best candidate water molecule is 
hydrogen-bonded to T206 and D237. In this case, D205 would only have a role in the 
formation of main chain distortion, which may trigger the cleavage of the scissile peptide 
bond. The conformational strain is reduced by the substitution of structurally important 
residues. These mutants thus have defective autocatalytic machineries that delay cleavage 
of the precursor. Compared to usual enzymatic catalysis, the autocatalytic cleavage of the 
peptide bond seems to be less efficient. It is worth emphasizing that in eukaryotic cells the 
activation of AGA occurs in the ER whereas the enzymatic catalysis takes place in the 
lysosomes, which could contribute to the lower efficiency of the autocatalytic cleavage 
when compared to the enzyme catalysis. 
 
CA and GCA processing is very similar to AGA including the removal of the signal 
sequence and the C-terminal peptide of the α-subunit (Kim et al. 2002, Kim et al. 2003). 
However, in AGA the second peptide bond cleavage is performed by a lysosomal 
protease, whereas in the case of CA and GCA the cleavage is probably performed 
autocatalytically by the enzyme molecule itself. As in other Ntn-hydrolases, the nucleophilic 
N-terminal residue of the β-subunit plays an essential role in catalysis and autocatalysis in 
GCA and CA. Furthermore, the precursor molecule structures are very similar to the native 
structure of the enzymes. During the activation of the GCA precursor a water molecule is 
utilized as a general base to deprotonate the hydroxyl group of S170. In addition, a bound 
water molecule seems to initiate the autoproteolytic activation of CA (Yoon et al. 2003). 
 
Ntn-hydrolases have a common structural fold with topological secondary structures. 
Although human AGA shares sequence similarity with other Ntn-hydrolases only in certain 
secondary elements, the autoproteolytic activation process shares several features with 
them (Ditzel et al. 1998, Xu et al. 1999, Kim et al. 2003): 1) The overall structure of the 
precursor and the active molecule is very similar. 2) The hydroxyl or sulfhydryl group of the 
nucleophile, which functions both as the catalytic and autocatalytic nucleophile, is oriented 
 towards the scissile peptide bond. 3) Conformational strain exists in the precursor at the 
cleavage site. 4) Water molecules are utilized in the activation process. Table 3 
summarizes the data on Ntn-hydrolases. 
 
 Human AGA 
Bacterial 
AGA 
PRO PGA GAT GCA CA 
Structure 
(αβ)2  hetero-
tetramer 
(αβ)2  
hetero-
tetramer 
7 member 
ring 
αβ dimer 
homo-
tetramer 
(αβ)2  hetero-
tetramer 
αβ hetero-
dimer 
Source human bacterial 
archaea 
yeast 
bacterial bacterial bacterial bacterial 
Catalytic 
function 
glycosyl-
asparaginase 
glycosyl-
asparagin
ase 
protease 
penicillin 
acylase 
amidotra-
nsferase 
deacylation 
of cephalo-
sporin 
deacylation 
of cephalo-
sporin  
Activation 
cleavage into 
subunits 
cleavage 
into 
subunits 
propeptide 
removal 
cleavage 
into 
subunits 
propeptide 
removal 
cleavage into 
subunits 
cleavage into 
subunits 
WT structure 
PDB code 
1apy, 1apz 
1ayy, 
2gaw 
1pma 1pnk, 1gk9 1gph, 1ecf 1or0 
1fm2, 1gk0, 
1gk1 
Nucleophile T206 T152 T1 S264 C1 S170 S1β 
Activation 
site 
H204-D205-
T206 
H150-
D151-
T152 
L-2 - G-1 -
T1 
T262-
G263-
S264 
E-2 - E-1 - 
C1 
Q168-G169-
S170 
Q168α-
G169α-S1β 
Oxyanion 
hole in 
catalysis 
T257, G258 
T203?, 
G204? 
L33/G47/ 
S129 
A332, 
N504 
N101, 
G102 
H192?, 
water? 
N244β, V70β
Precursor 
structure 
PDB code 
nd 
9gaa, 
9gac, 
9gaw, 
1p4k, 1p4v
1ryp  1e3a nd 1oqz 1keh 
Proposed 
oxyanion 
hole in auto-
catalysis 
T224? 
T170, 
water 
nd 
A332?, 
N504? 
N101?, 
G102? 
N413, H192 water, H23β 
Proposed 
general base 
in auto-
catalysis 
water/ D205 D151 water water? 
water?/ 
H70? 
water water 
Confor-
mational 
strain 
probable yes γ-turn probable probable yes probable 
Extra 
cleavage 
Q190-D191, 
E197-T198 
- - 
Y260-
P261 
- G160-D161 - 
 
Table 3. Summary of Ntn-hydrolases. 
 11. Characterization of AGU mutations (II) 
The 3D-structure of human AGA made it possible to analyze the structural consequences 
of AGU mutations. The AGU mutations affect the folding, dimerization, activation, or 
transport of the AGA molecule and reveal residues crucial for any of these necessary 
steps. To identify the molecular defect in aspartylglucosaminuria in uncharacterized 
patients, the patients genomic DNA was amplified by PCR with AGA specific primers. The 
nucleotide sequences of each exon, exon-intron boundaries, and untranslated regions 
were determined, and seven previously unknown mutations were identified. The novel 
mutations are schematically presented in Figure 10 in addition to previously published 
mutations. AGU mutations span the entire AGA cDNA except exon 5. The mutation 
spectrum is wide with missense and nonsense mutations, deletions, insertions, and 
splicing defects. 
 
 
 
Figure 10.  Map of the known AGU mutations. Nucleotide changes are presented above 
the exons. Corresponding changes at the polypeptide level are presented below the AGA 
precursor polypeptide. Substitutions are marked with a dot. Deletions are marked with a 
triangle; the lines connecting the label to the exon illustrate the deleted region. Insertions 
are marked with two lines, which part at the label end. The disease causing mutation of the 
AGUFin major allele is highlighted. 1,4Concurrent mutations. 2,3Compound heterozygote 
mutations. 5Two different mRNA species in a patient. Copyright (2001) Oxford University 
Press, UK. 
 11.1. Consequences of AGU mutations 
AGA cDNA was mutagenized to create the new mutation constructs which were 
expressed. The effects of the mutations on the maturation of the AGA polypeptide were 
studied using the SVpoly expression vector and transient expression in COS-1 cells. The 
processing of AGA polypeptides after chase times of 1, 3, and 6 hours was monitored. 
Among 28 AGU mutations studied, all but V12L revealed problems in intracellular 
processing and 24 prevented the activation cleavage in the ER. The intracellular 
distribution of AGA polypeptides was studied in Syrian golden hamster kidney cells (BHK-
21) where protein synthesis was stopped for three hours with cycloheximide to allow the 
proteins to be transported from the ER. Among 28 AGU mutations studied, 22 
demonstrated significant problems in the lysosomal targeting of AGA polypeptides. 
 
The mutations are here grouped according to the severity of the effect for the AGA 
polypeptide, judged based on intracellular maturation, lysosomal targeting, or activity. They 
are considered to cause mild, moderate, or severe effects. The clinical phenotype of AGU 
patients is reported to be relatively homogenous (Aula et al. 2001). However, the clinical 
details of the progression or severity of symptoms are unavailable and at this point it is not 
possible to reliably analyze if the severity of mutations at the polypeptide level is reflected 
in the clinical outcome of patients. 
 
11.1.1. Mutations with mild effects 
AGU mutations that produce intracellularly stabile precursor polypeptides and at least a 
fraction of normal subunits are here defined as mild. Intracellularly, these AGA 
polypeptides are seen in the Golgi compartment and lysosomes in addition to the ER. The 
polypeptides may also have detectable enzyme activity. 
 
The unpublished L15R mutation of the signal sequence is mild with 30% activity compared 
to the WT. Signal sequences typically contain many hydrophobic residues. The mutation is 
located in a long stretch of hydrophobic residues and thus it could affect polypeptide 
synthesis by delaying transport of AGA through the translocon complex. The other 
mutation of the signal peptide, V12L, had no effect on the AGA polypeptide. 
 
S72P disturbs packing of the molecule by introducing proline into a loop in the active site 
resulting in abnormal maturation of polypeptides. Also stabilization of T206 during catalysis 
is prevented. 
 
F135S mutation affects dimerization and subsequently activation by destabilizing the loop 
which contains H124 (see 10.1). 
 
 The tight backbone turn at G226 would be absent in the G226D substitution, since 
according to the Ramachandran plot such backbone torsion angles can only be allowed for 
glycine. The substitution might cause spatial problems and in any case the long side chain 
of aspartic acid would occupy the active site preventing normal processing. 
 
There are only a few AGU-causing active site mutations of AGA. So far, the only mutations 
of residues directly involved in catalysis are the homozygous S72P and the novel 
heterozygous mutation T257I. T257 and G258 form the oxyanion hole that stabilizes a 
covalent enzyme-substrate transition state (Tikkanen et al. 1996a). The larger isoleucine is 
unable to replace T257 during enzymatic catalysis. 
  
11.1.2. Mutations with moderate effects 
AGU mutations are here classified as moderate when they produce inactive precursor 
polypeptides, which remain unprocessed. These precursor polypeptides are retained in the 
ER and the majority of polypeptides face rapid degradation. 
 
The A42_A32insDA mutation disrupts an α-helix. The insertion most probably disturbs 
local folding in the ER, since the structural environment of A43 is restricted and the 
mutation changes the residue order of the helix. 
 
Similar outcome resulted from G60D mutation since the side chain of aspartic acid is 
excessively large for local structure and results in misfolding of the polypeptide. G100E 
and A101V disturb the three-dimensional structure of AGA because of space limitations 
and probably also affect dimerization of precursors. 
 
C163S substitution is responsible for defective folding and premature degradation in the 
AGUFin major mutation, R161Q+C163S. C163S causes structural problems in addition to 
preventing the formation of the disulfide bridge between C163 and C179 resulting in 
destabilization of the loop structure that provides contacts between the two αβ dimers of 
AGA. The reason the mutated polypeptides remain in the ER as monomeric precursor 
polypeptides is evidently that the initial folding is defective and dimerization is prevented 
(Riikonen et al. 1996). On the other hand, C163 is located very near to K177 and Y178, 
which form one of the three phosphotransferase recognition sites and the substitution also 
prevents phosphorylation by altering local folding (Tikkanen et al. 1997). 
  
The unstable precursor molecules produced by the novel mutations G252E and G252R 
can be explained by the fact that according to the Ramachandran plot the backbone 
torsion angles at 252 are only allowed for glycine. G302R, a neighbor of the oxyanion hole 
residue T257, also made the precursor unstable. 
  
The mutations with an abnormal C-terminus of the β-subunit produced unstable precursor 
polypeptides. Quite surprisingly, some precursor polypeptide could be observed with 
PAGE and immunofluorescence analyses (see 10.1). 
 
11.1.3. Mutations with severe effects 
AGU mutations, which make the AGA polypeptide remarkably unstable, are here defined 
as severe. Trace amounts of mutant polypeptides in this category are seen after a 6 h 
chase, but they do not represent normal AGA precursor or subunits. AGA polypeptide is 
undetectable in immunofluorescence analysis of transfected cells even with AGA 
antibodies against the denatured subunits. The mutant polypeptides are severely 
shortened by premature stop codons of the AGA gene. 
 
The only severe mutation with a point mutation is C306R. Replacement of the disulfide 
bond forming C306 with arginine results in total misfolding and rapid degradation of the 
synthesized polypeptides. The substitution disturbs the packing of the molecule. This is the 
determining factor in the misfolding, since C286S and C306S polypeptides were normally 
processed and active demonstrating that the disulfide bridge between C306 and C286 is 
not crucial for the early folding and stability of AGA (Riikonen et al. 1996). 
 
Table 4 lists the patient mutations and Figure 11 shows the locations of AGU point 
mutations in the 3D-structure of the WT molecule. 
  
Construct Processing Targeting 
Activity 
% WT 
Comments 
WT (Prec), pro-α, α, β Lysosomes 100  
COS-1   ≤ 7  
Mild mutations 
aV12L (Prec), pro-α, α, β Lysosomes 100 Like WT 
L15R Prec, pro-α, α, β ER, Lysosomes 30 May affect synthesis 
bS72P Prec, α, pro-β ER, Lysosomes 30 
Restricted space, affects packing, 
defective active site 
F135S Prec, pro-α, α, β ER, Lysosomes 12 Destabilization,affects dimerization 
G226D Prec, α, pro-β ER, Lysosomes ≤ 7 Tight backbone turn missing 
T257I Prec, α, pro-β ER, Lysosomes ≤ 7 
Defective active site, restricted 
space 
Moderate mutations 
A42_A43insDA Prec ER-trapped ≤ 7 Disrupts α-helix, affects packing 
G60D Prec ER-trapped ≤ 7 Restricted space 
G100E Prec ER-trapped ≤ 7 Restricted space 
A101V Prec ER-trapped ≤ 7 
Restricted space, affects 
dimerization 
R161Q+C163S Prec ER-trapped ≤ 7 
C163S: Restricted space, prevents 
SS-bridge formation and 
dimerization, defective targeting 
G252E Prec ER-trapped ≤ 7 Backbone torsion angle disallowed 
G252R ePrec ER-trapped ≤ 7 Backbone torsion angle disallowed 
P268fsX319 ePrec ER-trapped ≤ 7 C-terminus of β-subunit altered 
cS269fsX274 ePrec ER-trapped ≤ 7 C-terminus of β-subunit altered  
G302R Prec ER-trapped ≤ 7 Affects active site 
G314fsX378 fPrec ER-trapped ≤ 7 C-terminus of β-subunit altered  
aE334X ePrec ER-trapped ≤ 7 C-terminus of β-subunit missing  
Severe mutations 
dW34fsX45   ≤ 7 Short abnormal polypeptide 
bC64X   ≤ 7 
Short abnormal polypeptide, partial 
read-through into precursor  
E65fsX70   ≤ 7 Short abnormal polypeptide 
I112fsX127   ≤ 7 Short abnormal polypeptide 
dT123fsX142   ≤ 7 Short abnormal polypeptide 
T125fsX126   ≤ 7 Short abnormal polypeptide 
A132fsX146   ≤ 7 Short abnormal polypeptide 
W168X   ≤ 7 Short abnormal polypeptide 
L263X   ≤ 7 C-terminus of β-subunit missing 
C306R   ≤ 7 Restricted space, affects packing 
 
Table 4. Summary of immunoprecipitation, immunofluorescence, and activity 
measurement data in patient mutations. The novel mutations are shown in boldface type. 
aConcurrent mutations; b(Peltola et al. 1996), c(Fisher and Aronson 1991), d(Park et al. 
1993); eTruncated precursor; fElongated precursor. 
 
  
 
Figure 11. The locations of AGU point mutations. Only one α- and β-subunit of the AGA 
molecule is shown. The mild mutations are shown in yellow, moderate mutations are 
green, and the severe mutations are red. The α-helical and β-sheet layers typical for N-
hydrolases are indicated at the bottom. 
 
  
12. Expression and purification of recombinant human AGA precursor 
12.1. Expression of recombinant human AGA precursor 
Many post-translational modifications performed by higher eukaryotic cells are applied to 
proteins produced in yeast expression systems. These include processing of the signal 
sequences, disulfide bridge formation, and O- and N-linked glycosylation. Thus folding of 
recombinant proteins is generally very native-like. However, glycosylation is not identical to 
mammalian systems. In lower eukaryotes, O-linked oligosaccharides contain only 
mannose residues and N-glycosylation is also somewhat different from higher eukaryotes 
(Cregg et al. 2000). The two major yeast systems are Saccharomyces cerevisiae (Eckart 
and Bussineau 1996) and Pichia pastoris (Cregg et al. 2000). They lack detectable 
endotoxins and are generally regarded as safe. High expression levels of therapeutic 
proteins (up to 1.5 g/l) have been achieved using fermentation of P. pastoris (Wang et al. 
2001), which is capable of metabolizing methanol as its sole carbon source. 
 
The recombinant human AGA was produced in the yeast P. pastoris. The mutated AGA 
gene encoding the precursor form of the molecule was cloned in several tandem repeats 
into the yeast genome. The most efficiently producing clone was selected from several 
different vector and yeast strain combinations. The best clone utilized methanol to promote 
AGA expression which was approximately at the level of 14 mg/l. The precursor molecule 
was secreted into the culture medium using the signal sequence of AGA. Several batches 
of precursor expression were performed in baffled flasks. The production of the precursor 
using fermentation was also attempted. However, all precursor molecules were cut into two 
polypeptides during fermentation, which did not occur during the flask expression. During 
the expression, EDTA was used to inhibit metalloproteases and glycine was added to 
stabilize the precursor molecule. 
 
 12.2. Purification and crystallization of human AGA precursor 
Fusion protein vectors are increasingly popular. A fusion protein with a tag of known size 
and biological function can simplify the isolation, purification, and detection of the target 
protein and enhance the expression level and secretion. The tags can be helpful for 
stabilizing fused proteins and enhance their solubility. Expression tags were not used for 
the AGA precursor because the use of the short hydrophilic FLAG-epitope tag (Chubet and 
Brizzard 1996) or the HA-tag (Murray et al. 1995) in the termini or the loops of the WT AGA 
molecule was not successful (Kyttälä, A., personal communication). The tagged AGA 
molecules were either unstable or the tag was cleaved off by proteases. Thus it was 
necessary to utilize several liquid chromatography methods in the precursor purification 
scheme (Figure 12). The scheme utilized for the purification of the active enzyme was 
unsuccessful for the precursor and therefore a new scheme was developed. 
 
 
 
Figure 12. The AGA precursor after liquid chromatography purification steps. In the silver 
stained PAGE, shown are the raw material after AGA expression (RAW), and the sample 
after hydrophobic interaction chromatography (HIC), anion exchange chromatography 
(AEC), gel filtration (GF), and cation exchange chromatography (CEC). The precursor is 
cut into abnormal subunits during purification. The α1- and β1-subunits result from a cut 
between E197 and T198 while the α2- and β2-subunits result from a cut between Q190 
and D191. 
 
During purification, the AGA polypeptides were observed to aggregate when exposed to 
light. The aggregation was not dependent on temperature. Thus, the exposure of AGA 
samples to light during purification was minimized. The precursor molecule was slowly cut 
into subunits in spite of the use of protease inhibitor cocktail during the purification. N-
terminal sequencing revealed that the signal sequence had been normally cut out from the 
α-subunit but the β-subunits contained two abnormal N-termini (Kalkkinen, N., personal 
communication). The precursor had been cut 8 and 15 residues before the normal 
activation site between D205 and T206 (Figure 6). The cut at Q190-D191 occurred in the 
early steps of the purification, while the cut between E197 and T198 is visible only after 
anion exchange chromatography. Based on the bacterial precursor structure, the linker 
 peptide between the α- and β-subunits at these cut sites is located on the surface of the 
molecule and thus it is probable that yeast proteases are responsible for the hydrolysis of 
the peptide bonds. Transient expression in COS-1 cells with these cut site residues 
mutagenized individually and combined did not show aberrant precursor processing but 
these constructs were not further expressed in P. pastoris. The rate of cleavage was 
dependent on temperature and thus the purification steps were performed with cooled 
buffers. Table 5 summarizes the purification parameters for the AGA precursor after each 
purification step during the single largest precursor purification batch. The amount of 
purified precursor AGA totalled 686 µg (1.37% of the total protein). Overall, several 
milligrams of the AGA precursor was purified. 
 
Step Mass total 
protein, 
before (µg) 
Mass total 
protein, after 
(µg) 
Recovery 
total protein 
(%) 
Relative AGA 
amount (%) 
Relative AGA 
precursor amount 
(%) 
Initial 
concentration 
nd nd nd 22 15 
HIC 50214 32137 64.0 24 17 
AEC 25334 3536 14.0 74 52 
GF 3536 2493 70.5 84 54 
CEC 2100 937 44.6 84 46 
 
Table 5. Purification of recombinant human AGA precursor from P. pastoris. The values 
have been approximated by scanning and quantitating bands on SDS-PAGE using the 
Scion Image program (Scion Corporation). 
 
The separation of the molecules with different β-subunits proved very difficult. Two-
dimensional SDS PAGE was used to evaluate the purity and properties of the purified AGA 
sample. At the molecular weight corresponding to the precursor, three different dots were 
observed. The two major dots had a 0.16 pH unit difference. In addition, the α- and β-
subunits were observed. The different precursor molecules probably represented different 
glycosylation forms since the mass-spectrometric spectrum of the precursor showed 
several peaks whose mass-differences correspond to the mass of mannose (Kalkkinen, N., 
personal communication). The range of the sugar residues was 18-24 and the tallest peaks 
were at 19-20 residues. Thus in one N-glycosylation site the average oligosaccharide 
chain contained 2 GlcNAc residues and approximately 8 mannose residues, which 
corresponds well with the mammalian and the P. pastoris high-mannose glycosylation 
pattern (Miele et al. 1997a, Miele et al. 1997b). Upon cleavage of the oligosaccharide 
chains with Endoglycosidase H and Peptide:N-Glycosidase F, the resulting polypeptides 
were of equal size, further confirming that the oligosaccharide chains of the recombinant 
AGA precursor were high-mannose-type. The distribution of the oligosaccharide chains or 
the possible phosphorylation of the recombinant AGA precursor was not analyzed. 
 
 The purified AGA precursor samples were delivered to the University of Joensuu, where 
the crystallization experiments are conducted by Dr. Carita Oinonen. First small hollow 
cylindrical crystals were obtained and later larger crystals with a different form without a 
hollow center have been obtained (Figure 13). The best partial data set collected so far 
from a crystal reached 4.0 Å resolution, which is not sufficient enough for high-detail 
structure determination. Further crystallization experiments are still ongoing. 
 
 
Figure 13. Human AGA precursor crystals.  
 
 CONCLUDING REMARKS 
AGU was identified in 1968. Since the initial observations, excretion of glycoasparagines 
into urine and lysosomal accumulation of the substrates of AGA, the AGA enzyme has 
become one of the best characterized lysosomal enzymes. The AGU mutations have 
provided clues about structurally and functionally important residues. Prior to this study, 
the role of disulfide bonds and oligosaccharide chains, and the expression, intracellular 
processing, lysosomal transport, the three-dimensional structure, and the enzymatic 
mechanism of the AGA had been characterized in detail. Moreover, initial characterization 
of the dimerization and activation had been carried out. In addition, using the AGU mouse 
model therapeutic approaches to treat AGU had been initiated. 
 
This study has elucidated the critical steps in the early stages of AGA maturation in the 
ER. The activation of newly synthesized AGA precursors requires proper folding and 
dimerization of the precursor polypeptides and numerous AGU mutations deliver their 
consequences by disturbing this process. The dimerization was found to be dependent on 
three regions of amino acids at the dimer interface of the AGA molecule. The activation of 
human AGA precursors was found to occur autocatalytically. The side chain of T206 was 
demonstrated to have a central role in the autocatalysis. In addition, the conformation of 
the polypeptide backbone at the activation site was suggested to be strained. An activation 
mechanism for AGA autocatalysis was proposed. Later, the structural similarity of the 
endogenous bacterial AGA precursor and the active enzyme, published by others, also 
demonstrated that the activation of AGA occurs autocatalytically and conformational strain 
was found in the activation site. However, the bacterial activation mechanism still 
contained significant amount of speculation concerning the roles of individual residues. 
 
More active site residues were explored to confirm the activation mechanism of human 
AGA. The results strongly suggested that the previous mechanism was still valid. Without 
the human AGA precursor structure the detailed roles of the residues involved in activation 
still remained unresolved apart from T206 and D205. Several structurally important 
residues were identified which contribute to the activation by stabilizing and interacting with 
the core residues of activation. 
 
In addition, seven novel AGU mutations were found and characterized along with 
previously found mutations. The results provided evidence that structural changes caused 
by missense mutations are the most common cause of AGU disease. They result in folding 
problems and destabilization of AGA polypeptides by introducing large residues to limited 
spaces in three-dimensional structure, by affecting active site residues, by creating 
electrostatic disturbances, or by preventing disulfide bond formation. The predicted and 
observed consequences of AGA mutations were in good agreement. 
  
This molecular characterization of activation site mutations and AGU mutations contributes 
to the expanding body of knowledge pertaining to AGU disease pathogenesis. After 
molecular characterization of the consequences of these mutations, details of AGA 
dimerization and activation are now better defined and a more comprehensive structure-
function understanding of AGA has been obtained. 
 
Three-dimensional structure of the human AGA precursor would provide a valuable tool 
that could be used to engineer drugs for AGU treatment. Additionally, enzyme replacement 
and gene therapy may prove to be efficient in AGU treatment, and future challenges in 
AGU research include further development of therapeutic methods to alleviate the suffering 
of AGU patients and their families. This study provides some data which can be utilized to 
reach the goal. While efficient corrective methods are unavailable, the ethical aspects of 
genetic counseling and testing should be carefully considered.  
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